Sample ID	Alterations	Biomarker	Drugs	Diseases	Response	Evidence	Match	Source	BioM	Resist.	Tumor type
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	complete		PRAD
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	complete		OV
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	complete		OV
input01	CHEK2 MUT* (--)	CHEK2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;AACR 2015 (abstr CT322);FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input01	DNMT3A (R885S)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	NO	PMID:22417203	complete		AML
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
input01	DPYD MUT* (--), DPYD MUT* (P179A)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
input01	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene	969.0	BRCA
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D816)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal, Myelodisplasic syndrome, Myelodisplasic proliferative syndrome, Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Systemic mastocytosis	Resistant	A	NO	FDA	only alteration type		GIST, MDS, MDPS, HES, ECL, CML, ALL, SM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (T670I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	PMID:24687822	only alteration type		GIST
input01	NPM1 MUT* (--)	NPM1 oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	NO	PMID:22417203	only alteration type		AML
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	NO	EMA	only gene		HES, ECL
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input01	PDGFB MUT* (P26L)	PDGFB-COL1A1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Dermatofibrosarcoma	Responsive	A	NO	FDA	only gene		DFS
input01	PTCH1 (P568L)	PTCH1 oncogenic mutation	Vismodegib(SHH inhibitor)	Basal cell carcinoma, Medulloblastoma	Responsive	A	NO	PMID:19726763;PMID:19726761	complete		BCC, MB
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET (618,620,634,768,791,891,918,C634W,M918T)	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	A	NO	PMID:20065189;PMID:22025146	only alteration type		THCA
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT splice acceptor variant	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type	755.0	CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT biallelic inactivation	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type	755.0	CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Cisplatin(Chemotherapy)	Any cancer type	Increased Toxicity (Ototoxicity)	A	YES	FDA	only alteration type	755.0	CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT splice acceptor variant	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT biallelic inactivation	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Mercaptopurine(Purine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT splice acceptor variant	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT biallelic inactivation	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
input01	TPMT MUT* (--), TPMT MUT* (--), TPMT MUT* (--)	TPMT (A80P,Y240C,A154T,A167G)	Thioguanine(Guanine analog)	Any cancer type	Increased Toxicity (Myelosupression)	A	YES	FDA	only alteration type		CANCER
input01	TSC1 (S1043-)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		GCA
input01	TSC1 (S1043-)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	complete		RA
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA, GCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	complete		BRCA
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)	only gene		TH
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET oncogenic mutation	Selpercatinib(RET kinase inhibitor)	Thyroid medullary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only alteration type		THM
input01	BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	complete		OV
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	complete		OV
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
input01	ATM (R2746M)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	complete		PRAD
input01	BRIP1 MUT* (A440V)	BRIP1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	complete		PRAD
input01	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
input01	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
input01	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete	751.0	COREAD
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)	Ripretinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
input01	MET (H997Y)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
input01	MET (H997Y)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
input01	NTRK1 (A425V)	NTRK1 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	YES	FDA:https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
input01	NTRK1 (A425V)	NTRK1 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	YES	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Pralsetinib(Tyrosine kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung	only gene		NSCLC
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input01	RAD51C MUT* (T365)	RAD51C oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input01	RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input01	RAD54L MUT* (--), RAD54L MUT* (--)	RAD54L oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
input01	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	only alteration type		NSCLC
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
input01	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
input01	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
input01	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
input01	ERBB2 MUT* (--)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
input01	BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Thyroid	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)	only gene		TH
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Selpercatinib(RET kinase inhibitor)	Solid tumors	Responsive	A	YES	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors	only gene		SOLID
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	complete		PRAD
input01	ATM (R2746M)	ATM oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
input01	ATR MUT* (--), ATR MUT* (--), ATR MUT* (--), ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	complete		PRAD
input01	CHEK2 MUT* (--)	CHEK2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input01	MLH1 MUT* (--)	MLH1 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input01	RAD51C MUT* (T365)	RAD51C oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
input01	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
input01	BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
input01	BTK MUT* (G618), BTK MUT* (--), BTK MUT* (--)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	NO	PMID: 28418267	only alteration type		CLL
input01	NTRK1 (A425V)	NTRK1 (G595R)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210861s008lbl.pdf	only alteration type		SOLID
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	complete		PLEN
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	MAP2K2 MUT* (--)	MAP2K2 oncogenic mutation	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Cabozantinib(Kinase inhibitor )	Non-small cell lung	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input01	BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input01	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
input01	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input01	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
input01	MET (H997Y)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input01	MET (H997Y)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input01	MET (H997Y)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input01	MET (H997Y)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	complete		PAAD
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
input01	BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
input01	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
input01	AKT1 MUT* (E117-)	AKT1 (Q79K,E17K)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265152	only alteration type		CM
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF oncogenic mutation	BRAF inhibitor + MEK inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	ENA 2014 (abstr 428)	only alteration type		COREAD
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	AKT inhibitors	Any cancer type	Responsive	D	YES	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	only alteration type		CANCER
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
input01	BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	non-allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only alteration type		HNSC
input01	AKT1 MUT* (E117-)	AKT1 (H238Y)	Everolimus(MTOR inhibitor)	Fibrous histiocytoma	Responsive	C	NO	ASCO 2015 (abstr 11010)	only alteration type		FH
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	NO	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	NO	NCT02186821	only gene		HEMATO
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	NO	PMID:24491302;NCT02270034	only gene		LY, GB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	NO	PMID:20979472;PMID:24687827	only gene		IM, THCA
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	NO	PMID:26032424	only alteration type		AML
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
input01	APC MUT* (--)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	only alteration type		COREAD
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR amplification	AR inhibitor next gens	Prostate adenocarcinoma	Responsive	D	NO	PMID:23589709;PMID:21859989	only gene		PRAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25520391	only gene		COREAD
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N), AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR (F877L) + AR (T878A)	Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:27196756	only alteration type		PRAD
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF (S214C)	Sorafenib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	http://www.jci.org/articles/view/72763;PMID:24569458	only alteration type		LUAD
input01	ARID1A MUT* (P16-), ARID1A MUT* (SG186-187S)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	only alteration type		CANCER
input01	ARID1A MUT* (P16-), ARID1A MUT* (SG186-187S)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	only alteration type		OV
input01	ARID1A MUT* (P16-), ARID1A MUT* (SG186-187S)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	only alteration type		CANCER
input01	GLI2 MUT* (--), GLI2 MUT* (S1550F)	GLI2 amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
input01	ATM (R2746M)	ATM oncogenic mutation	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	complete		COREAD
input01	ATM MUT* (--), ATM (R2746M)	ATM deletion	ATR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A48)	only gene		COREAD
input01	ATM (R2746M)	ATM oncogenic mutation	DNA-PKc inhibitors	Lymphoma	Responsive	D	NO	PMID:23761041	complete		LY
input01	ATM MUT* (--), ATM (R2746M)	ATM deletion	DNA-PKc inhibitors	Lymphoma	Responsive	D	NO	PMID:23761041	only gene		LY
input01	ATM (R2746M)	ATM oncogenic mutation	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	complete		ST
input01	ATM MUT* (--), ATM (R2746M)	ATM deletion	PARP inhibitors	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	only gene		ST
input01	ATM MUT* (--), ATM (R2746M)	ATM biallelic inactivation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	NO	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only alteration type		BCL
input01	ATM (R2746M)	ATM oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	complete		BLCA
input01	ATM MUT* (--), ATM (R2746M)	ATM deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
input01	ATM (R2746M)	ATM oncogenic mutation	Olaparib(PARP inhibitor)	Stomach	Responsive	C	NO	ENA 2014 (abstr 8LBA)	complete		ST
input01	ATM (R2746M)	ATM oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	complete		G
input01	ATR MUT* (--), ATR MUT* (--), ATR MUT* (--), ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
input01	ATR MUT* (--), ATR MUT* (--), ATR MUT* (--), ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
input01	ATR MUT* (--), ATR MUT* (--), ATR MUT* (--), ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
input01	AURKA MUT* (--)	AURKA amplification	AURK inhibitors	Prostate adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:22302096;PMID:22389870	only gene		PRAD, CANCER
input01	IGF2 MUT* (--)	IGF2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25632036	only gene		COREAD
input01	BAP1 MUT* (MV615-616IM)	BAP1 oncogenic mutation	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only alteration type		MESO
input01	BAP1 MUT* (MV615-616IM)	BAP1 deletion	EZH2 inhibitors	Mesothelioma	Responsive	D	NO	PMID:26437366	only gene		MESO
input01	BAP1 MUT* (MV615-616IM)	BAP1 oncogenic mutation	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only alteration type		CM
input01	BAP1 MUT* (MV615-616IM)	BAP1 deletion	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22038994	only gene		CM
input01	BAP1 MUT* (MV615-616IM)	BAP1 oncogenic mutation	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only alteration type		R, CANCER
input01	BAP1 MUT* (MV615-616IM)	BAP1 deletion	PARP inhibitors	Renal, Any cancer type	Responsive	D	YES	PMID:22683710	only gene		R, CANCER
input01	BCOR MUT* (K392), BCOR MUT* (--)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
input01	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
input01	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
input01	BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
input01	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
input01	BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
input01	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
input01	BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
input01	BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
input01	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
input01	BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
input01	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
input01	BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
input01	BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
input01	BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
input01	BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
input01	BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type	802.0	LUAD
input01	BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type	802.0	LUAD
input01	BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
input01	BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
input01	BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
input01	BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
input01	BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
input01	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	NO	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
input01	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
input01	BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
input01	BRCA2 (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	complete		OV
input01	BRCA2 (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	complete		CM
input01	BRCA2 (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	complete		BRCA
input01	BRCA2 (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	complete		BRCA
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	complete		OV
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	complete		PA
input01	BRCA2 (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	complete		BRCA
input01	CBL MUT* (H36-), CBL MUT* (P596S)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:23696637	only alteration type		MDPS
input01	CBL MUT* (H36-), CBL MUT* (P596S)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:23696637	only alteration type		MDPS
input01	CDH1 (AL10-11A)	CDH1 oncogenic mutation	Bicalutamide(AR inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	complete		BRCA
input01	CDKN2A (-?-51)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	complete		CM
input01	CDKN2A (-?-51)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	complete		G, CANCER
input01	CDKN2A (-?-51)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
input01	CDKN2A (-?-51)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
input01	CDKN2A (-?-51)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	complete		CANCER
input01	CDKN2A (-?-51)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
input01	CHEK2 MUT* (--)	CHEK2 deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322)	only gene		PRAD
input01	MAP2K1 MUT* (--)	MAP2K1 (P124)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:25370473	only alteration type		CM
input01	MAP2K1 MUT* (--)	MAP2K1 (Q56P,P124S,P124L;C121S)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:21383288	only alteration type		CM
input01	MAP2K1 MUT* (--)	MAP2K1 oncogenic mutation	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26030179	only alteration type		COREAD
input01	MAP2K1 MUT* (--)	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	MEK inhibitors	Any cancer type	Resistant	D	YES	PMID:19915144	only alteration type		CANCER
input01	MAP2K1 MUT* (--)	MAP2K1 (P124L,K57N,C121S)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144;PMID:23444215;PMID:21383288	only alteration type		CM
input01	MAP2K1 MUT* (--)	MAP2K1 (Q56P,P124S,P124L)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:19915144	only alteration type		CM
input01	CRLF2 MUT* (--), CRLF2 MUT* (--), CRLF2 MUT* (--)	CRLF2 fusion	BET inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:22904298	only gene		ALL
input01	CRLF2 MUT* (--), CRLF2 MUT* (--), CRLF2 MUT* (--)	CRLF2 fusion	MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:22955920	only gene		ALL
input01	CSF1R MUT* (--), CSF1R MUT* (T482I), CSF1R MUT* (--)	CSF1R (Y571D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:18971950	only alteration type		MDPS
input01	CSF3R MUT* (P551L)	CSF3R frameshift variant (D771),frameshift variant (S783)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Atypical chronic myeloid leukemia	Responsive	D	NO	PMID:23656643	only alteration type		ACML
input01	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
input01	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	BRAF inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:22328973	only alteration type	802.0	LUSC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 (S768R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	C	NO	PMID:22328973	only alteration type	802.0	LUSC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 (S768R)	Erlotinib(EGFR inhibitor 1st gen)	Lung squamous cell	Responsive	C	NO	PMID:22328973	only alteration type	816.0	LUSC
input01	MAP2K2 MUT* (--)	MAP2K2 (Q60P)	MEK inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265154	only alteration type		CM
input01	MAP2K2 MUT* (--)	MAP2K2 (V35M,L46F,N126D,C125S)	MEK inhibitors	Cutaneous melanoma	Resistant	D	NO	PMID:24265153	only alteration type		CM
input01	MET (H997Y)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
input01	MET (H997Y)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
input01	MET (H997Y)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
input01	MYCN MUT* (S377L), MYCN (E390K)	MYCN amplification	SMO inhibitors	Medulloblastoma	Resistant	D	NO	PMID:24951114	only gene		MB
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	complete		NB
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	complete		L
input01	EPHA2 (S193F)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
input01	EPHA2 (S193F)	EPHA2 (G391R)	MTOR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type		LUSC
input01	EPHA2 (S193F)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene	802.0	CANCER
input01	EPHA2 (S193F)	EPHA2 amplification	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:18047674;PMID:19010823;PMID:19861960	only gene	802.0	CANCER
input01	EPHA2 (S193F)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type	802.0	LUSC
input01	EPHA2 (S193F)	EPHA2 (G391R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung squamous cell	Responsive	D	NO	PMID:20360610	only alteration type	802.0	LUSC
input01	ERBB2 MUT* (--)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
input01	ERBB2 MUT* (--)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
input01	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
input01	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
input01	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
input01	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
input01	RAC1 MUT* (--), BRAF MUT* (--)	RAC1 (P29S) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:25056119	only alteration type		CM
input01	ERBB2 MUT* (--)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
input01	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
input01	ERBB2 MUT* (--)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
input01	ERBB2 MUT* (--)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
input01	RAC1 MUT* (--), BRAF MUT* (--)	RAC1 (P29S) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:25056119	only alteration type		CM
input01	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
input01	ERBB2 MUT* (--)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
input01	ERBB2 MUT* (--)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
input01	STK11 MUT* (--)	STK11 oncogenic mutation	BET inhibitors	Lung	Resistant	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
input01	ERBB2 MUT* (--)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type	969.0	BRCA, CANCER
input01	ERBB2 MUT* (--)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type	969.0	CANCER
input01	ERBB2 MUT* (--)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (P262H,G284R)	ERBB3 mAb inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (P262H,G284R,Q809R)	PI3K pathway inhibitor + MEK inhibitors	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (G284R,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	ASCO 2015 (abstr e15516)	only alteration type		BLCA
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (G284R,V104M,R103G)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only alteration type		BLCA
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (P262H,G284R,Q809R)	Lapatinib(ERBB2 inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (P262H,G284R)	Pertuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type		CANCER
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 (P262H,G284R,Q809R)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:23680147	only alteration type	969.0	CANCER
input01	ERBB4 MUT* (R1174), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
input01	ERBB4 MUT* (R1174), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	complete		LIP
input01	ERCC2 MUT* (--), ERCC2 MUT* (--), ERCC2 MUT* (--), ERCC2 MUT* (--)	ERCC2 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:25096233	only alteration type		BLCA
input01	ERCC6 (GG445-446G)	ERCC6 oncogenic mutation	Cisplatin(Chemotherapy)	Ovary	Responsive	D	NO	PMID:25634215	complete	755.0	OV
input01	NTRK1 (A425V)	NTRK1 (G595R,G667C)	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26546295	only alteration type		COREAD
input01	ERBB4 MUT* (R1174), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
input01	FAT1 (Q3707*), FAT1 (V3428X)	FAT1 oncogenic mutation	BET inhibitors	Head an neck squamous	Responsive	D	NO	PMID:27397505	complete		HNSC
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	complete		BRCA
input01	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	PMID:27870574	only gene		LUSC
input01	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Endometrium	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		ED
input01	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Lung squamous cell	Responsive	C	NO	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)	only gene		LUSC
input01	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors	Head an neck	Responsive	D	NO	PMID:23418312	only gene		HNC
input01	FGFR1 MUT* (--)	FGFR1 amplification	FGFR inhibitors(Lucitanib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR amplification	Abiraterone(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:26537258	only gene		PRAD
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR (L702H,T878A)	Abiraterone(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:26537258	only alteration type		PRAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR (F877L)	Arn-509(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:23779130	only alteration type		PRAD
input01	FGFR4 MUT* (--), FGFR4 MUT* (S137)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
input01	FLCN MUT* (A358V), FLCN MUT* (L322), FLCN MUT* (E46K)	FLCN oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:23995526	only alteration type		R
input01	FLCN MUT* (A358V), FLCN MUT* (L322), FLCN MUT* (E46K)	FLCN deletion	Everolimus(MTOR inhibitor)	Thyroid	Responsive	C	NO	PMID:25295501	only gene		TH
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	complete		PLEN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
input01	FOXA1 (GD157-158D)	FOXA1 amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
input01	GNAS MUT* (--)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
input01	HDAC2 MUT* (-11-12X), HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
input01	BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
input01	INPP4B MUT* (S891F), INPP4B MUT* (--), INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
input01	INPP4B MUT* (S891F), INPP4B MUT* (--), INPP4B MUT* (--), INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
input01	JAK1 MUT* (--)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:22955920;PMID:18805579	only alteration type		ALL
input01	JAK3 MUT* (--)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	NO	PMID:22705984	only alteration type		LY
input01	JAK3 MUT* (--)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	NO	PMID:18397343	only alteration type		MKB
input01	KCNJ5 MUT* (--), KCNJ5 MUT* (F343L), KCNJ5 MUT* (--)	KCNJ5 (L168R)	Amiloride(Na-Ca chanel blocker)	Adrenal adenoma	Responsive	D	NO	PMID:24506072	only alteration type		AA
input01	KCNJ5 MUT* (--), KCNJ5 MUT* (F343L), KCNJ5 MUT* (--)	KCNJ5 (L168R)	Verapamil(Na-Ca chanel blocker)	Adrenal adenoma	Responsive	D	NO	PMID:24506072	only alteration type		AA
input01	KDR MUT* (P1133S), KDR MUT* (--), KDR MUT* (--)	KDR (A1065T)	VEGFR inhibitors	Any cancer type	Responsive	D	YES	PMID:24569783	only alteration type		CANCER
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 11	HSP90 inhibitors	Gastrointestinal stromal	Responsive	C	NO	PMID:22898035	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9 or 17	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:21737509	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:19671763	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Systemic mastocytosis	Responsive	C	NO	PMID:18559612	only alteration type		SM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	C	NO	PMID:18986703	only alteration type		AML
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D816Y,D816F,D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:16397263	only alteration type	802.0	CANCER
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (N822K)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	D	NO	PMID:23149070	only alteration type		AML
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT inframe deletion (416-422),inframe insertion (416-422)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Acute myeloid leukemia	Responsive	D	NO	PMID:15618474	only alteration type		AML
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT inframe deletion (V560)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	NO	PMID:15201427	only alteration type		THYM
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	complete		COREAD
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	complete		FGCT, MGCT
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D820Y)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23775962	only alteration type		CM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (Y553N)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	NO	PMID:21969494	only alteration type		THYM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:22068222;PMID:25695690	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	C	NO	PMID:22119758;PMID:21456006	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D820Y)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:25695690	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (788-828,829-860,550-592)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (A829P,V654A,T670I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:25239608	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT inframe deletion (577-579)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	NO	PMID:20970876	only alteration type		THYM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9 or 11	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:22270258	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (550-592,627-664,788-828,829-860)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:18936790;PMID:20372153	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 17	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:23840364	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D820E)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	NO	PMID:19461405	only alteration type		THYM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	NO	PMID:19861435	only alteration type		THYM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	NO	PMID:19861435	only alteration type		THYM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (Y553N)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	C	NO	PMID:23375402	only alteration type		THYM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
input01	MET (H997Y)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	complete		L
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR (F877L)	Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:23779130	only alteration type		PRAD
input01	IGF1R MUT* (--)	IGF1R amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung adenocarcinoma	Resistant	D	NO	PMID:24458568	only gene		LUAD
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	complete		L
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
input01	MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
input01	MAP2K1 MUT* (--)	MAP2K1 (F129L,L215P,I103N,P124)	ERK inhibitors	Any cancer type	Responsive	D	YES	PMID:23614898	only alteration type		CANCER
input01	MAP2K1 MUT* (--)	MAP2K1 (P124)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:25370473	only alteration type		CM
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	complete		MPN
input01	MAP2K1 MUT* (--)	MAP2K1 (C121S)	novel MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:24448821	only alteration type		CM
input01	MAP2K1 MUT* (--)	MAP2K1 (K57T)	Panitumumab + Trametinib(EGFR mAb inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26644315	only alteration type		COREAD
input01	MAP2K1 MUT* (--)	MAP2K1 inframe deletion (56-60)	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only alteration type		OV
input01	MAP2K1 MUT* (--)	MAP2K1 (Q56P)	Trametinib(MEK inhibitor)	Any cancer type	Responsive	D	YES	PMID:26582713	only alteration type		CANCER
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
input01	MAP2K1 MUT* (--), BRAF MUT* (--)	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:22588879	only alteration type		CM
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	complete		G
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR (T878A)	Flutamide(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:2260966	only alteration type		PRAD
input01	MET (H997Y)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
input01	MET (H997Y)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
input01	SLC29A1 MUT* (--), SLC29A1 MUT* (--)	SLC29A1 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Resistant	D	NO	PMID:21166756	only alteration type		BLCA
input01	MET (H997Y)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
input01	MET (H997Y)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
input01	MET (H997Y)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
input01	BTK MUT* (G618), BTK MUT* (--), BTK MUT* (--)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	NO	PMID:25082755	only alteration type		MCL
input01	MET (H997Y)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
input01	MET (H997Y)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
input01	MET (H997Y)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
input01	MET (H997Y)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
input01	MET (H997Y)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
input01	MET (H997Y)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
input01	MET (H997Y)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
input01	MET (H997Y)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
input01	MET (H997Y)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
input01	PLCG2 MUT* (--), PLCG2 MUT* (--), PLCG2 MUT* (--)	PLCG2 (R665W,L845F)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	C	NO	PMID:24869598	only alteration type		CLL
input01	MET (H997Y), BRAF MUT* (--)	MET amplification + BRAF (V600E)	Crizotinib + Vemurafenib(ALK inhibitor + BRAF inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27325282	only gene		COREAD
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (627-664,664-714,449-514)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458;PMID:18955451;PMID:16624552	only alteration type		GIST
input01	MET (H997Y), ERBB2 MUT* (--)	MET amplification + ERBB2 amplification	Crizotinib + Trastuzumab(ALK inhibitor + ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:26432108	only gene		ST
input01	MET (H997Y), ERBB2 MUT* (--)	MET amplification + ERBB2 amplification	Crizotinib + Trastuzumab(ALK inhibitor + ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:26432108	only gene		ST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 17 or 18	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:21690468;PMID:21642685	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT amplification	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:23775962	only gene		CM
input01	MPL (EE155-156EK)	MPL (W515F)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:16834459	only alteration type		MDPS
input01	MSH3 (G32E)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	complete		CANCER
input01	MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
input01	MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23582185;PMID:21689725;PMID:17259998	only alteration type		GIST
input01	MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
input01	MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
input01	MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
input01	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
input01	MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
input01	MYC MUT* (Q48-)	MYC amplification	BET inhibitors	Myeloma, Neuroblastoma	Responsive	D	NO	PMID:21889194;PMID:23430699	only gene		MYMA, NB
input01	MYC MUT* (Q48-)	MYC amplification	CDK7 inhibitors	Neuroblastoma	Responsive	D	NO	PMID:25416950	only gene		NB
input01	MYC MUT* (Q48-)	MYC amplification	FACT inhibitors	Neuroblastoma	Responsive	D	NO	PMID:26537256	only gene		NB
input01	MYC MUT* (Q48-)	MYC amplification	PIM inhibitors	Prostate adenocarcinoma	Responsive	D	NO	PMID:25505253	only gene		PRAD
input01	MYC MUT* (Q48-)	MYC amplification	Temozolomide(Chemotherapy)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	complete		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	NO	PMID:22573716;PMID:19727076	complete		G, LK
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	NO	PMID:22573716;PMID:19727076	only gene		G, LK
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	NO	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	complete		G, MPN, LK
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	NO	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	complete		CM
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	complete		CM
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	complete		G
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	NO	PMID:12660384	only alteration type		HES
input01	ERBB2 MUT* (--)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
input01	MET (H997Y), ERBB2 MUT* (--)	MET amplification + ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Stomach	Resistant	D	NO	PMID:22238368	only gene		ST
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	complete		HNC, SG
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	complete		NF
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
input01	LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (S2508F), LRP1B MUT* (--), LRP1B MUT* (G1159), LRP1B MUT* (E273K)	LRP1B oncogenic mutation	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only alteration type		OV
input01	LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (--), LRP1B MUT* (S2508F), LRP1B MUT* (--), LRP1B MUT* (G1159), LRP1B MUT* (E273K)	LRP1B deletion	Liposomal Doxorubicin(Chemotherapy)	Ovary	Resistant	C	NO	PMID:22896685	only gene		OV
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	complete		HC
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	complete		PLEN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	complete		PLEN, MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	complete		PLEN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	complete		PLEN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	complete		G
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	complete		MPN
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
input01	ERBB2 MUT* (--)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	complete		G
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	complete		CM
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	complete		G
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	complete		G
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
input01	ERBB2 MUT* (--)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input01	MET (H997Y)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input01	BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:19318552	complete		ALL
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:19246562	complete		ALL
input01	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (S1911F), NOTCH1 (FP1617-1618FS), NOTCH1 MUT* (--), NOTCH1 (W287*), NOTCH1 (G248S)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:16688224;PMID:23033986	only gene		ALL
input01	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (S1911F), NOTCH1 (FP1617-1618FS), NOTCH1 MUT* (--), NOTCH1 (W287*), NOTCH1 (G248S)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	NO	ASCO 2006 (abstr 6585)	complete		ALL
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	complete		ALL
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	complete		BRCA
input01	NOTCH1 (S1911F), NOTCH1 (FP1617-1618FS), NOTCH1 (W287*), NOTCH1 (G248S)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	NO	PMID:22210878	complete		MCL
input01	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (S1911F), NOTCH1 (FP1617-1618FS), NOTCH1 MUT* (--), NOTCH1 (W287*), NOTCH1 (G248S)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	complete		CANCER
input01	NOTCH1 (FP1617-1618FS)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	complete		CANCER
input01	NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 (M1I), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
input01	NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 (M1I), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	NO	PMID:25564152	only alteration type		BRCA, AML, ALL
input01	NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 (M1I), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	YES	NCT01859741;NCT01277146	only alteration type		SOLID
input01	NPM1 MUT* (--)	NPM1 oncogenic mutation	DOT1L inhibitors + MLL1 inhibitors	Acute myeloid leukemia	Responsive	D	NO	PMID:27535106	only alteration type		AML
input01	NRG1 MUT* (--)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
input01	NRG1 MUT* (--)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
input01	NTRK1 (A425V)	NTRK1 fusion	Pan-TK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24162815	only gene		LUAD
input01	NTRK1 (A425V)	NTRK1 fusion	Pan-TKR inhibitors	Any cancer type	Responsive	C	YES	PMID:28183697;ASCO 2017 (LBA2501)	only gene		CANCER
input01	NTRK1 (A425V)	NTRK1 fusion	Pan-TK inhibitors(Entrectinib,etc)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26546295	only gene		COREAD
input01	NTRK1 (A425V)	NTRK1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2013 (abstr 8023)	only gene		LUAD
input01	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
input01	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
input01	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
input01	PAK1 MUT* (D496N)	PAK1 amplification	PAK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23535073	only gene		CM
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only alteration type		PRAD
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only alteration type		PA
input01	PALB2 MUT* (--)	PALB2 deletion	PARP inhibitors	Prostate adenocarcinoma	Responsive	C	NO	AACR 2015 (abstr CT322);PMID:26510020	only gene		PRAD
input01	PALB2 MUT* (--)	PALB2 deletion	PARP inhibitors	Pancreas	Responsive	D	NO	PMID:25263539;NCT01585805	only gene		PA
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only alteration type		PA
input01	PALB2 MUT* (--)	PALB2 deletion	Mytomycin C(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:21135251	only gene		PA
input01	PALB2 MUT* (--)	PALB2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
input01	PALB2 MUT* (--)	PALB2 deletion	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only gene		PA
input01	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
input01	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET (I788N)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Lung adenocarcinoma	Resistant	D	NO	PMID:28615362	only alteration type		LUAD
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
input01	PDPK1 MUT* (--)	PDPK1 amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:19602588	only gene		BRCA
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	complete		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	complete		L, COREAD
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	complete		BLCA, HNC, L
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	complete		BRCA, OV, CESC, ED
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	complete		HNSC
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	complete		G, THCA
input01	MET (H997Y)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	complete		ST
input01	NF1 (LDS2661-2663X), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only alteration type		CM
input01	PIK3CA (P466L), ERBB2 MUT* (--)	PIK3CA oncogenic mutation + ERBB2 amplification	Everolimus + Trastuzumab + Chemotherapy(MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:27091708	only gene		BRCA
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only gene		CM
input01	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	AKT inhibitors	Glioma	Responsive	D	NO	PMID:23166678	only alteration type		G
input01	PIK3R1 MUT* (--)	PIK3R1 oncogenic mutation	PI3K pathway inhibitors	Endometrium	Responsive	C	NO	ASCO 2015 (abstr 11075)	only alteration type		ED
input01	POLE MUT* (--), POLE MUT* (--)	POLE (268-471)	PD1 Ab inhibitors	Glioma, Endometrium	Responsive	C	NO	PMID:27001570;PMID:27683556;PMID:27159395	only alteration type		G, ED
input01	POLE MUT* (--), POLE MUT* (--)	POLE oncogenic mutation	PD1 Ab inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28188185	only alteration type		COREAD
input01	PTCH1 (P568L)	PTCH1 oncogenic mutation	SMO inhibitors	Medulloblastoma	Responsive	D	NO	PMID:24651015	complete		MB
input01	PTCH1 (P568L)	PTCH1 oncogenic mutation	Foretinib(MET inhibitor)	Medulloblastoma	Responsive	D	NO	PMID:25391241	complete		MB
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 11	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT mutation in exon 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT amplification	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:22261812	only gene		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	complete		PLEN
input01	PTPRD (D1822N)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	complete		S
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
input01	NF1 (LDS2661-2663X)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	complete		OS
input01	RAD51C MUT* (T365)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
input01	RAD51C MUT* (T365)	RAD51C oncogenic mutation	PARP inhibitors	Ovary	Responsive	C	NO	ASCO 2015 (abstr 5508)	only alteration type		OV
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
input01	RB1 MUT* (--)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
input01	RB1 MUT* (--)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
input01	RB1 MUT* (--)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
input01	RB1 MUT* (--)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
input01	RB1 MUT* (--)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
input01	RB1 MUT* (--)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	RET inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22327624;PMID:22327622	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET-TPCN1 fusion	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only gene		TH
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET (C634W,M918T)	RET inhibitors	Thyroid	Responsive	D	NO	PMID:23056499	only alteration type		TH
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET-TPCN1 fusion	Cabozantinib(Pan-kinase inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET (C634W,M918T)	Cabozantinib(Pan-kinase inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Nintedanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26787234	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Sunitinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET-TPCN1 fusion	Sunitinib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET (C634W,M918T)	Sunitinib(Pan-TK inhibitor)	Thyroid	Responsive	D	NO	PMID:21470995	only alteration type		TH
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Vandetanib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:28447912	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET-TPCN1 fusion	Vandetanib(Pan-TK inhibitor)	Thyroid carcinoma	Responsive	D	NO	PMID:21470995	only gene		THCA
input01	RICTOR MUT* (L13F)	RICTOR amplification	MTORC1/2 inhibitors	Lung	Responsive	C	NO	PMID:26370156	only gene		L
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	NO	PMID:24875859	only gene		IM
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
input01	ERBB2 MUT* (--)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
input01	HGF MUT* (--), HGF MUT* (--), ERBB2 MUT* (--)	HGF amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:22850551	only gene		BRCA
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
input01	SERPINB3 MUT* (G353A)	SERPINB3 oncogenic mutation	CTLA4 inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:27668655	only alteration type		CM
input01	SF3B1 MUT* (--)	SF3B1 (K700E,K666N)	Spliceosome inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858	only alteration type		CANCER
input01	MET (H997Y), ERBB2 MUT* (--)	MET amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:22850551	only gene		BRCA
input01	SMARCA1 MUT* (--), SMARCA1 MUT* (--), SMARCA1 MUT* (--), SMARCA1 MUT* (--)	SMARCA1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
input01	SMARCA4 MUT* (--)	SMARCA4 oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only alteration type		OV
input01	SMARCA4 MUT* (--)	SMARCA4 deletion	EZH2 inhibitors	Ovary	Responsive	C	NO	ESMO 2015 (abstract 302)	only gene		OV
input01	MET (H997Y), ERBB2 MUT* (--)	MET amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Stomach	Resistant	C	NO	PMID:22850551; PMID:26432108	only gene		BRCA, ST
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO (P641A)	Vismodegib(SHH inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 9062)	only alteration type		L
input01	STAG2 MUT* (--), STAG2 MUT* (H832D)	STAG2 oncogenic mutation	PARP inhibitors	Glioma	Responsive	D	NO	PMID:24356817	only alteration type		G
input01	BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
input01	STK11 MUT* (--)	STK11 oncogenic mutation	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only alteration type		LUAD
input01	STK11 MUT* (--)	STK11 deletion	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only gene		LUAD
input01	STK11 MUT* (--)	STK11 oncogenic mutation	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only alteration type		CANCER
input01	STK11 MUT* (--)	STK11 deletion	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only gene		CANCER
input01	STK11 MUT* (--)	STK11 oncogenic mutation	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only alteration type		LUAD
input01	STK11 MUT* (--)	STK11 deletion	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only gene		LUAD
input01	STK11 MUT* (--)	STK11 (D194E)	Everolimus(MTOR inhibitor)	Pancreas	Responsive	C	NO	PMID:21189378	only alteration type		PA
input01	STK11 MUT* (--)	STK11 oncogenic mutation	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only alteration type		LUAD
input01	STK11 MUT* (--)	STK11 deletion	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only gene		LUAD
input01	BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
input01	MAP2K1 MUT* (--)	MAP2K1 (E203K,Q56P,K57E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23569304	only alteration type		CM
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
input01	SUZ12 MUT* (--)	SUZ12 oncogenic mutation	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only alteration type		CANCER
input01	SUZ12 MUT* (--)	SUZ12 deletion	BET inhibitors	Any cancer type	Responsive	D	YES	PMID:25119042	only gene		CANCER
input01	SYK MUT* (--), SYK MUT* (--), SYK MUT* (--), SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	NO	PMID:16409295;PMID:19549911	only gene		MCL, CLL
input01	TERT MUT* (C89)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
input01	TOP2A MUT* (--), TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
input01	TP53 (H179Q), TP53 (V122X)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
input01	NF1 (LDS2661-2663X), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only alteration type		CM
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	complete		HNC
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only gene		CM
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	NO	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	complete		BCL
input01	TP53 (H179Q), TP53 (V122X)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	NO	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	NO	PMID:27959731	complete		AML, MDPS
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	complete		OV
input01	TP53 (H179Q), TP53 (V122X)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	NO	PMID:25409149	complete		THYM
input01	TP53 (H179Q), TP53 (V122X)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	NO	PMID:25409149	only gene		THYM
input01	MET (H997Y), BRAF MUT* (--)	MET amplification + BRAF (V600E)	Vemurafenib + Panitumumab(BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27325282	only gene		COREAD
input01	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
input01	TSC1 (S1043-)	TSC1 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	complete		RA
input01	TSC1 (S1043-)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	complete		BLCA
input01	TSC1 (S1043-)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	complete		R
input01	TSC1 (S1043-)	TSC1 oncogenic mutation	Everolimus(MTOR inhibitor)	Sarcoma, Stomach	Responsive	C	NO	PMID:26859683	complete		S, ST
input01	TSC1 (S1043-)	TSC1 deletion	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)	only gene		R
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only alteration type		LAM
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO (D473H)	Vismodegib(SHH inhibitor)	Medulloblastoma	Resistant	C	NO	PMID:19726788;PMID:25759019	only alteration type		MB
input01	VEGFA MUT* (DR3-4X)	VEGFA amplification	Sorafenib(Pan-TK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24687604	only gene		HC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	Vismodegib(SHH inhibitor)	Basal cell carcinoma	Resistant	C	NO	PMID:25759020;PMID:25306392	only alteration type		BCC
input01	ZNRF3 (DS550-551D)	ZNRF3 oncogenic mutation	Porcupine inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:26023187	complete		COREAD
input01	EWSR1 MUT* (--)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
input01	FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Lung squamous cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		LUSC
input01	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		CM
input01	BRCA2 (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	complete		OV
input01	BRCA2 (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
input01	MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
input01	MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
input01	ERCC2 MUT* (--), ERCC2 MUT* (--), ERCC2 MUT* (--), ERCC2 MUT* (--)	ERCC2 (G665A,P463L,R601Q,A717G,D423N,R487W,E606G,R631C,V242F,V536M,.,L461V,D609E,Y24C,D513Y,D609G,N238S)	Cisplatin	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERCC2	only alteration type		BLCA
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
input01	NTRK1 (A425V)	NTRK1 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/NTRK1|CIVIC=https://civicdb.org/genes/3983/summary	only gene		CANCER
input01	MET (H997Y)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
input01	MET (H997Y)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,D816.,N655K,K642E,V560D,W557C,D60N,D816H)	Sunitinib + Sorafenib	Thymic	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		THYM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (Y823D,T670I,V654A,D820G,C809G,D820A,N822K,D816H)	Imatinib	Gastrointestinal stromal	Resistant	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		GIST
input01	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		HIS
input01	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
input01	MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
input01	MTOR MUT* (--)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		CANCER
input01	TSC1 (S1043-)	TSC1 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	only gene		RCCC
input01	TSC1 (S1043-)	TSC1 (H105R,H206D,V220F,L180P,F216A,M224R,H68R,.,S35Q,F158C,L117P,L191H)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC1	complete		RCCC
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
input01	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
input01	KDM6A MUT* (--), KDM6A MUT* (--), KDM6A (P1159S)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
input01	KDM6A (P1159S)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	complete		BLCA
input01	MET (H997Y)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,N655K,V560D,K642E,D816.,W557C,D60N,D816H)	Imatinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT amplification	Imatinib	Cutaneous melanoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT (D816)	Blu-285	Mastocytosis	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		MAS
input01	CDKN2A (-?-51)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	complete		CANCER
input01	CDKN2A (-?-51)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only alteration type		RCCC
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
input01	ERBB2 MUT* (--)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	Azd5363	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/AKT1|CIVIC=https://civicdb.org/genes/2/summary	only alteration type		BRCA
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	Azd5363	Endometrial adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		EDA
input01	AKT1 MUT* (E117-)	AKT1 (E17K)	Azd5363	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		OV
input01	MET (H997Y)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
input01	BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
input01	NF1 MUT* (--), NF1 MUT* (--), NF1 (LDS2661-2663X)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
input01	NF1 (LDS2661-2663X)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	complete		CANCER
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Histiocytoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ARAF	only alteration type		HIS
input01	FGFR1 MUT* (--)	FGFR1 amplification	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1-BCR fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1-CEP110 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1-CUX1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1-ERLIN2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1-TACC1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1-FGFR1OP1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	FGFR1 MUT* (--)	FGFR1 (V592M,K687E,.,N577K)	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only alteration type		CANCER
input01	FGFR1 MUT* (--)	FGFR1-ZNF198 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1	only gene		CANCER
input01	PIK3CA (P466L)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	complete		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
input01	ATM (R2746M)	ATM (R2832C,T1743I,R2642S,S2592C,.,R2032K,D2870A,V2424G,N2875K,L590R,R3008C)	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	complete		CANCER
input01	ATM MUT* (--), ATM (R2746M)	ATM deletion	Olaparib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/ATM	only gene		CANCER
input01	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 fusion	Entrectinib	Any cancer type	Responsive	C	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK2	only gene		CANCER
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only alteration type		THM
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET-KIF5B fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET-CCDC6 fusion	Larotrectinib + 292 + 667	Thyroid medullary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/RET	only gene		THM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT amplification	Sunitinib + Sorafenib	Thymic	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		THYM
input01	MET (H997Y)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
input01	BRCA2 (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	complete		BRCA
input01	BRCA2 (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Sorafenib	Non-small cell lung	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary	only alteration type		NSCLC
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
input01	MAP2K1 MUT* (--)	MAP2K1 (V60E,H119P,L115P,I103N,F53C,R49L,G128V,V60M,L177V,F53S,P124L,T28I,P124S,Q56P,L37P,Y130C,I204T,E203K,I111R,I111A,F53L,.,L177M,V154I,C121S,S123T,P306H,V211D,I111P,K57T,D67N,I111N,P124Q,R47Q,K57N,S218D,F129L,S222D,E144K,L115R,G128D,K57E)	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MAP2K1	only alteration type		OV
input01	NTRK1 (A425V)	NTRK1 (G595R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK1	only alteration type		CANCER
input01	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
input01	MET (H997Y)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
input01	MET (H997Y)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input01	ABCC3 MUT* (--)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
input01	AKT1 MUT* (E117-)	AKT1 E17K	Akt Inhibitor MK2206	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/231	only alteration type		BRCA
input01	AKT1 MUT* (E117-)	AKT1 E17K	Capivasertib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/709	only alteration type		BRCA
input01	AKT1 MUT* (E117-)	AKT1 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4029	only alteration type		CM
input01	AKT1 MUT* (E117-)	AKT1 E17K	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/707	only alteration type		CM
input01	AKT1 MUT* (E117-)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/439	only alteration type		CM
input01	AKT1 MUT* (E117-)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4498	only alteration type		CM
input01	AKT1 MUT* (E117-)	AKT1 Q79K	Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6260	only alteration type		CM
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
input01	ALK MUT* (--), ALK MUT* (--), ALK MUT* (V448)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
input01	APC MUT* (--)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	only alteration type		COREAD
input01	AR MUT* (L272), AR MUT* (P377S), AR (Y835N)	AR W742	Bicalutamide	Prostate adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/448	only alteration type		PRAD
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/17	only alteration type		NSCLC
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF S214C	Sorafenib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/40	only alteration type		NSCLC
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF S214C	Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/41	only alteration type		NSCLC
input01	ARAF MUT* (--), ARAF MUT* (--), ARAF MUT* (--)	ARAF S490T	Cetuximab,Irinotecan,Vemurafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1905	only alteration type		COREAD
input01	ASNS MUT* (D138Y)	ASNS Amplification	Asparaginase	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/953	only gene		OV
input01	ASS1 MUT* (--), ASS1 MUT* (--), ASS1 MUT* (--), ASS1 MUT* (--)	ASS1 Loss	Carboplatin,Cisplatin,Taxol	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/5989	only gene		OV
input01	ATM (R2746M)	ATM Mutation	Temozolomide	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/453	complete		CM
input01	ATM (R2746M)	ATM Mutation	Temozolomide	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/452	complete		GB
input01	ATM (R2746M)	ATM Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8505	complete		PRAD
input01	BAP1 MUT* (MV615-616IM)	BAP1 Mutation	Sunitinib,Everolimus	Renal	Resistant	B	NO	https://civicdb.org/links/evidence_items/5339	only alteration type		R
input01	BAP1 MUT* (MV615-616IM)	BAP1 Mutation	Valproic Acid,Trichostatin A,Vorinostat,Panobinostat	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1234	only alteration type		UVM
input01	BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	YES	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
input01	BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
input01	BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
input01	BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
input01	BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
input01	BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	YES	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
input01	BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
input01	BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
input01	BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
input01	BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
input01	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
input01	BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
input01	BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
input01	BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
input01	BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
input01	BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
input01	BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
input01	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
input01	BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
input01	BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
input01	BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
input01	BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
input01	BRCA2 (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
input01	BRCA2 (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
input01	BRCA2 (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	complete		OV
input01	BRCA2 (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	complete		OV
input01	BRCA2 (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
input01	BRCA2 (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
input01	BRCA2 (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
input01	BRCA2 (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
input01	BRIP1 MUT* (A440V)	BRIP1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11208	only alteration type		PRAD
input01	CDKN2A (-?-51)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	complete		CH
input01	CDKN2A (-?-51)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	complete		PA
input01	CDKN2A (-?-51)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
input01	CDKN2A (-?-51)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
input01	CDKN2A (-?-51)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
input01	CDKN2A (-?-51)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
input01	CHEK2 MUT* (--)	CHEK2 mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11205	only alteration type		PRAD
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 G253C	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/266	only alteration type		NSCLC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 G505S	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/267	only alteration type		NSCLC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 G774V	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/268	only alteration type		NSCLC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 I638F	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/269	only alteration type		NSCLC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 L239R	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/270	only alteration type		NSCLC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 L63V	Dasatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/271	only alteration type		NSCLC
input01	DDR2 (R752H), DDR2 MUT* (T836)	DDR2 S768R	Dasatinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/272	only alteration type		NSCLC
input01	DNMT3A (R885S)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/1587	complete		AML
input01	DNMT3A (R885S)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	NO	https://civicdb.org/links/evidence_items/11	only alteration type		AML
input01	DNMT3A (R885S)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/18	only alteration type		AML
input01	EGFR wildtype	EGFR Wildtype	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2512	complete		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
input01	ERBB2 MUT* (--)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	only alteration type		BLCA
input01	ERBB2 MUT* (--)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
input01	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene	969.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene	969.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene	969.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene	972.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene	972.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene	972.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene	972.0	BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
input01	ERBB2 MUT* (--)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
input01	ERBB3 MUT* (I117), ERBB3 MUT* (--), ERBB3 MUT* (--), ERBB3 MUT* (C1078Y)	ERBB3 V855A	Pertuzumab,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1845	only alteration type		NSCLC
input01	ERBB4 MUT* (R1174), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
input01	FGFR1 MUT* (--)	FGFR1 FGFR1OP2::FGFR1	Ponatinib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7380	only gene		AML
input01	FGFR1 MUT* (--)	FGFR1 Fusion	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7375	only gene		AML
input01	FGFR1 MUT* (--)	FGFR1 N546K	Pemigatinib	Pilocityc astrocytoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10325	only alteration type		PIA
input01	FGFR1 MUT* (--)	FGFR1 ZNF198::FGFR1	Midostaurin	Malignant peripheral nerve sheat tumor	Responsive	C	NO	https://civicdb.org/links/evidence_items/1104	only gene		MPN
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1911	only gene		BLCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Afimoxifene	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1105	only gene		BRCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1909	only gene		BRCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1604	only gene		BRCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	FGFR Inhibitor AZD4547	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1991	only gene		BRCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Pazopanib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7246	only gene		BRCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Lucitanib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7488	only gene		BRCA
input01	FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Lung squamous cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/680	only gene		LUSC
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Infigratinib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/1908	only gene		LUSC
input01	FGFR1 MUT* (--)	FGFR1 Amplification	PD173074	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/686	only gene		NSCLC
input01	FGFR1 MUT* (--)	FGFR1 Amplification	Dovitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3027	only gene		NSCLC
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	only alteration type		UVM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	only alteration type		UVM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	only alteration type		UVM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	only alteration type		UVM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
input01	GNAQ MUT* (Q88*), GNAQ MUT* (--)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
input01	GNAS MUT* (--)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
input01	JAK1 MUT* (--)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
input01	KDR MUT* (P1133S), KDR MUT* (--), KDR MUT* (--)	KDR R1032Q	Cabozantinib,Dovitinib,Axitinib,Lenvatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/9339	only alteration type		COREAD
input01	KDR MUT* (P1133S), KDR MUT* (--), KDR MUT* (--)	KDR R961W	Regorafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1191	only alteration type	775.0	COREAD
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT A502_Y503insAY	Regorafenib,Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4630	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT A502_Y503insAY	Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7392	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT A829P	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7413	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT A829P	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7415	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT C809G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2920	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D579del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4142	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D816E	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4631	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D816E	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7401	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D816H	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2923	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D816V	Midostaurin	Systemic mastocytosis	Responsive	B	NO	https://civicdb.org/links/evidence_items/1725	only alteration type		SM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D820A	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2921	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D820G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2922	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D820Y	Imatinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2886	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D820Y	Sunitinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2888	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT D820Y	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4589	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT K550_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4062	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT K550_W557del	Ponatinib,Regorafenib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4583	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT K558delinsNP	Imatinib,Regorafenib,Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4594	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT K642E	Dasatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4147	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT K642E	Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7397	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT L576P	Nilotinib,Sorafenib,Imatinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/34	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT L576P	Dasatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/42	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT L576P	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4136	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT L576P	Nilotinib,Dasatinib,Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/303	only alteration type		NSCLC
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT Mutation	Imatinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1222	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT Mutation	Pictilisib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/919	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7370	only alteration type		AML
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Ponatinib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7379	only alteration type		AML
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2918	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4167	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4169	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7414	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT N822K	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4595	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT S628N	Imatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7463	only alteration type		CM
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2924	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT T670I	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4510	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7416	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT T670I	Sunitinib,Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7417	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V559D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/3028	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V559D	Imatinib,Regorafenib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4459	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V560D	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4122	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V560D	Regorafenib,Ponatinib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4127	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V560G	Ponatinib,Regorafenib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7395	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V654A	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/249	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT V654A	Sunitinib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/304	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT W557_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4082	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT W557_K558del	Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4084	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT W557_K558del	Regorafenib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4087	only alteration type		GIST
input01	KIT MUT* (DSKFYKMIKEGF876-887DX)	KIT Y823D	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2919	only alteration type		GIST
input01	KMT2C (SL3788-3789X), KMT2C MUT* (--), KMT2C MUT* (S338L), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
input01	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
input01	MAP2K1 MUT* (--)	MAP2K1 C121S	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1602	only alteration type		CM
input01	MAP2K1 MUT* (--)	MAP2K1 K57N	Selumetinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2936	only alteration type		LUAD
input01	MAP2K1 MUT* (--)	MAP2K1 P124S	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/12	only alteration type		CM
input01	MAP2K1 MUT* (--)	MAP2K1 Q56P	Selumetinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/13	only alteration type		CM
input01	MET (H997Y)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
input01	MET (H997Y)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
input01	MET (H997Y)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
input01	MET (H997Y)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
input01	MET (H997Y)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
input01	MET (H997Y)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
input01	MET (H997Y)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
input01	MET (H997Y)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
input01	MET (H997Y)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
input01	MET (H997Y)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
input01	MET (H997Y)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
input01	MET (H997Y)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
input01	MET (H997Y)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
input01	MET (H997Y)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
input01	MET (H997Y)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
input01	MET (H997Y)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
input01	MET (H997Y)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
input01	MRE11 MUT* (V273)	MRE11 Loss	Talazoparib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/876	only gene		ED
input01	MS4A1 MUT* (--)	MS4A1 Mutation	R-CHOP Regimen	Difuse large B Cell lymphoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/10367	only alteration type		DLBCL
input01	MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
input01	MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
input01	MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
input01	MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
input01	MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
input01	MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
input01	MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
input01	MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
input01	MTOR MUT* (--)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	only alteration type		BLCA
input01	MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
input01	MYCN MUT* (S377L), MYCN (E390K)	MYCN Amplification	FACT Complex-targeting Curaxin CBL0137	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/744	only gene		NB
input01	MYCN MUT* (S377L), MYCN (E390K)	MYCN Amplification	Panobinostat,JQ1	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6019	only gene		NB
input01	NFE2L2 MUT* (--)	NFE2L2 Mutation	Sapanisertib	Lung squamous cell	Responsive	B	NO	https://civicdb.org/links/evidence_items/7446	only alteration type		LUSC
input01	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (S1911F), NOTCH1 (FP1617-1618FS), NOTCH1 MUT* (--), NOTCH1 (W287*), NOTCH1 (G248S)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
input01	NPM1 MUT* (--)	NPM1 W288FS	NSC348884	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/152	only alteration type		AML
input01	NRG1 MUT* (--)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
input01	NRG1 MUT* (--)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
input01	NRG1 MUT* (--)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
input01	NTRK1 (A425V)	NTRK1 Fusion	Larotrectinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/978	only gene		COREAD
input01	NTRK1 (A425V)	NTRK1 Fusion	Larotrectinib,Lestaurtinib,Crizotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1019	only gene		LUAD
input01	NTRK1 (A425V)	NTRK1 Fusion	Larotrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/6567	only gene		SOLID
input01	NTRK1 (A425V)	NTRK1 Fusion	Entrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/11124	only gene		SOLID
input01	NTRK1 (A425V)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2960	only gene		COREAD
input01	NTRK1 (A425V)	NTRK1 LMNA::NTRK1	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/8900	only gene		COREAD
input01	NTRK1 (A425V)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1868	only gene		NSCLC
input01	NTRK1 (A425V)	NTRK1 SQSTM1::NTRK1	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2950	only gene		NSCLC
input01	NTRK1 (A425V)	NTRK1 Amplification	Larotrectinib	Solid tumors	Responsive	C	YES	https://civicdb.org/links/evidence_items/10170	only gene		SOLID
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 ETV6::NTRK2	Larotrectinib	Acute myeloid leukemia	Responsive	C	NO	https://civicdb.org/links/evidence_items/6396	only gene		AML
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 Fusion	Larotrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/10392	only gene		SOLID
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 Fusion	Entrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/11222	only gene		SOLID
input01	NTRK2 MUT* (--), NTRK2 (G621S)	NTRK2 KANK1::NTRK2	Larotrectinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/10361	only gene		GB
input01	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
input01	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
input01	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7994	only gene		AML
input01	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
input01	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
input01	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
input01	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
input01	PALB2 MUT* (--)	PALB2 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8504	only alteration type		PRAD
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7378	only gene		AML
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
input01	PDGFRA MUT* (--), PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
input01	PDGFRB MUT* (--), PDGFRB MUT* (G674E), PDGFRB MUT* (S82F)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	complete		BRCA
input01	PIK3CA (P466L)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	complete		COREAD
input01	PIK3CA (P466L)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	complete		ED
input01	PIK3CA (P466L)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	complete		ED
input01	PIK3CA (P466L)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	complete		HNSC
input01	PIK3CA (P466L)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	complete		HNSC
input01	PIK3CA (P466L)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	complete		NSCLC
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
input01	PIK3CA (P466L), PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
input01	PIK3R1 MUT* (--)	PIK3R1 Mutation	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1612	only alteration type		BRCA
input01	POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
input01	POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
input01	POLE MUT* (--), POLE MUT* (--)	POLE Mutation	Pembrolizumab	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1862	only alteration type		ED
input01	PREX2 MUT* (R263), PREX2 MUT* (--), PREX2 (D1139N), PREX2 MUT* (--)	PREX2 R172I	Vemurafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6268	only alteration type		CM
input01	PTPRD (D1822N)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	complete		HNSC
input01	RAC1 MUT* (--)	RAC1 P29S	Dabrafenib,Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/873	only alteration type		CM
input01	RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
input01	RAD54L MUT* (--), RAD54L MUT* (--)	RAD54L Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11207	only alteration type		PRAD
input01	RB1 MUT* (--)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET CCDC6::RET	Agerafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7480	only gene		COREAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET CCDC6::RET	Nintedanib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1601	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Cabozantinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4847	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4848	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Vandetanib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4849	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4850	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7066	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Selpercatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/8850	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Pralsetinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11233	only gene		NSCLC
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET Fusion	Selpercatinib	Thyroid carcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/8852	only gene		THCA
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET KIF5B::RET	Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/698	only gene		LUAD
input01	RET MUT* (LL15-16L), RET MUT* (--)	RET KIF5B::RET	Vandetanib,Everolimus	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1622	only gene		LUAD
input01	RICTOR MUT* (L13F)	RICTOR Amplification	Onatasertib,Sapanisertib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1440	only gene		LUAD
input01	RICTOR MUT* (L13F)	RICTOR Amplification	Vistusertib	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7449	only gene		SCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
input01	ROS1 MUT* (--), ROS1 (P1108L), ROS1 MUT* (K1026), ROS1 MUT* (S701F), ROS1 MUT* (--)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
input01	RUNX1 MUT* (--), RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	NO	https://civicdb.org/links/evidence_items/411	only alteration type		AML
input01	SF3B1 MUT* (--)	SF3B1 K666N	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1418	only alteration type		BRCA
input01	SF3B1 MUT* (--)	SF3B1 K700E	Spliceostatin A	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1417	only alteration type		BRCA
input01	SMAD4 MUT* (I94)	SMAD4 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/719	only alteration type		COREAD
input01	SMARCA4 MUT* (--)	SMARCA4 Loss	Abemaciclib,Palbociclib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/7155	only gene		NSCLC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO D473H	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/755	only alteration type		BCC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4653	only alteration type		BCC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO L412F	Vismodegib	Basal cell carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4654	only alteration type		BCC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO Mutation	Vismodegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/746	only alteration type		BCC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO Mutation	Vismodegib,Sonidegib	Basal cell carcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1477	only alteration type		BCC
input01	SMO MUT* (MD286-287X), SMO MUT* (--), SMO MUT* (--)	SMO Mutation	PSI,Arsenic Trioxide	Basal cell carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/747	only alteration type		BCC
input01	STK11 MUT* (--)	STK11 Mutation	Pembrolizumab,Nivolumab,Atezolizumab	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6441	only alteration type		LUAD
input01	STK11 MUT* (--)	STK11 Loss	Selumetinib,Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1144	only gene		NSCLC
input01	STK11 MUT* (--)	STK11 Loss	Everolimus,Sirolimus	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1620	only gene		NSCLC
input01	TLK2 MUT* (Q703*)	TLK2 Amplification	Go6983,GF109203X	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6000	only gene		BRCA
input01	TOP1 MUT* (--)	TOP1 Amplification	Irinotecan	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/888	only gene	984.0	COREAD
input01	TP53 (H179Q), TP53 (V122X)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
input01	TP53 (H179Q), TP53 (V122X)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	complete		BRCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	complete		BRCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	complete		NSCLC
input01	TP53 (H179Q), TP53 (V122X)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	YES	https://civicdb.org/links/evidence_items/7540	complete		SOLID
input01	TP53 (H179Q), TP53 (V122X)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	complete		ST
input01	TP53 (H179Q), TP53 (V122X)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
input01	TP53 (H179Q), TP53 (V122X)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
input01	TP53 (H179Q), TP53 (V122X)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
input01	TP53 (H179Q), TP53 (V122X)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
input01	TP53 (H179Q), TP53 (V122X)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
input01	TSC2 MUT* (S739), TSC2 MUT* (P1109)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
input02	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	FDA	only gene		LUAD
input02	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf	only gene		NSCLC
input02	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf	only gene		NSCLC
input02	ALK MUT* (--)	ALK inframe insertion (1151T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165	only alteration type		LUAD
input02	ALK MUT* (--)	ALK (L1196M,S1206Y,G1269A,I1171T)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	A	NO	PMID:24670165;PMID:24327273	only alteration type		LUAD
input02	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
input02	ALK MUT* (--)	ALK fusion	Brigatinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc	only gene		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s026lbl.pdf	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s028lbl.pdf	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf	only alteration type		CM
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	PMID:26510020;PMID: 32343890;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	only alteration type		PRAD
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA	only alteration type		OV
input02	DNMT3A MUT* (--)	DNMT3A oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	NO	PMID:22417203	only alteration type		AML
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD splice donor variant	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD biallelic inactivation	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD (I560S,D949V)	Capecitabine(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s051lbl.pdf	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD splice donor variant	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD biallelic inactivation	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD (I560S,D949V)	Flourouracil(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	FDA	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD splice donor variant	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD biallelic inactivation	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
input02	DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--), DPYD MUT* (--)	DPYD (I560S,D949V)	Tegafur(Fluoropyrimidine)	Any cancer type	Increased Toxicity	A	YES	PMID:23988873	only alteration type		CANCER
input02	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L858R)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L858R)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L861Q,G719,S768I)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L858R)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (T790M)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Ado-Trastuzumab Emtansine(EGFR mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor);Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		ST, GEJA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf	only gene		BRCA
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN	only alteration type		CM
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT (D816)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal, Myelodisplasic syndrome, Myelodisplasic proliferative syndrome, Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Systemic mastocytosis	Resistant	A	NO	FDA	only alteration type		GIST, MDS, MDPS, HES, ECL, CML, ALL, SM
input02	KIT MUT* (P166L)	KIT (T670I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	PMID:24687822	only alteration type		GIST
input02	NPM1 MUT* (--)	NPM1 oncogenic mutation	Daunorubicin(Chemotherapy)	Acute myeloid leukemia	Responsive	A	NO	PMID:22417203	only alteration type		AML
input02	EGFR MUT* (--)	EGFR (T790M)	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia	Responsive	A	NO	EMA	only gene		HES, ECL
input02	PDGFRA MUT* (--)	PDGFRA inframe deletion (I843)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input02	EGFR MUT* (--)	EGFR (T790M)	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Regorafenib(Pan-kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA (552-596,631-668,814-854)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines	only alteration type		GIST
input02	ROS1 MUT* (F383)	ROS1 fusion	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf	only gene		NSCLC
input02	TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Renal angiomyolipoma    , Giant cell astrocytoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf	only alteration type		RA, GCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Neratinib(ERBB2 inhibitor) + Capecitabine(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) + Docetaxel(Chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor) + Letrozole(Hormone therapy)	Breast adenocarcinoma	Responsive	A	NO	FDA;PMID:19786658	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Margetuximab(ERBB2 inhibitor) 	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Tucatinib(ERBB2 inhibitor) + Trastuzumab(ERBB2 inhibitor) + Capecitabine(chemotherapy)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569	only gene		BRCA
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022;PMID: 30110579	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	NCCN guideline Breast cancer 2022	only alteration type		BRCA
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Trametinib(MEK inhibitor) + Dabrafenib(BRAF inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (S786I,G719, L861Q)	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Niraparib(PARP inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer;PMID:30948273	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor) + Bevacizumab(VEGF mAb inhibitor)	Ovary	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary	only alteration type		OV
input02	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR (L858R)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN Non-Small Cell Lung Cancer guidlines 2022;FDA:https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (T790M)	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	FGFR2 MUT* (--)	FGFR2 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
input02	CDK12 MUT* (--)	CDK12 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input02	CHEK1 MUT* (--)	CHEK1 oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input02	FANCL MUT* (--)	FANCL oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate;PMID: 32795228	only alteration type		PRAD
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 fusion	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only gene		BLCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (G370C,R248C,S249C,Y373C)	Erdafitinib(FGFR inhibitor)	Bladder	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma:PMID:31340094	only alteration type		BLCA
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309	only alteration type		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Pembrolizumab(PD-1 blocking antibody) + Trastuzumab(ERBB2 mAb inhibitor) + Fluoropyrimidine (Chemotherapy) + Platinum (Chemotherapy)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120	only gene		ST, GEJA
input02	KRAS wildtype	KRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
input02	KRAS wildtype	KRAS wildtype	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	PMID: 19339720	complete		COREAD
input02	KIT MUT* (P166L)	KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)	Ripretinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981	only alteration type		GIST
input02	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Mobocertinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Amivantamab(EGFR mAb inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
input02	FGFR2 MUT* (--)	FGFR2 fusion	Infigratinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 fusion	Pemigatinib(FGFR kinase inhibitor)	Cholangiocarcinoma	Responsive	A	NO	FDA;PMID:32203698	only gene		CH
input02	PDGFRA MUT* (--)	PDGFRA exon 18 mutations	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Avapritinib(Kinase inhibitor)	Gastrointestinal stromal	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation;PMID:32615108	only alteration type		GIST
input02	MET MUT* (--)	MET exon 14 skipping mutations	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer;PMID:31279006;PMID:34036238	only alteration type		NSCLC
input02	MET MUT* (--)	MET exon 14 skipping mutations	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metastatic-non-small-cell-lung-cancer	only alteration type		NSCLC
input02	ROS1 MUT* (F383)	ROS1 fusion	Entrectinib(Pan-TK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA;PMID:28183697;ESMO 2019 (abstr 4178) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s007lbl.pdf	only gene		NSCLC
input02	RAD51B MUT* (--), RAD51B MUT* (--), RAD51B MUT* (--)	RAD51B oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input02	RAD51D MUT* (--), RAD51D MUT* (--)	RAD51D oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890	only alteration type		PRAD
input02	PIK3CA MUT* (--)	PIK3CA (C420R,E542K,E545A,E545D,E545G,E545K,H1047L,H1047R,H1047Y,Q546E,Q546R)	Alpelisib(PI3K inhibitor) + Fulvestrant(Estrogen receptor antagonist)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Stomach, Gastroesophageal junction adenocarcinoma	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas	only gene		ST, GEJA
input02	ERBB2 (G346D)	ERBB2 oncogenic mutation	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Non-small cell lung	Responsive	A	NO	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung	complete		NSCLC
input02	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib(Pan-TK inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc	only gene		SOLID
input02	NTRK3 MUT* (--)	NTRK3 fusion	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions	only gene		SOLID
input02	NTRK3 MUT* (--)	NTRK3 (F617L,G623R,G696A)	Larotrectinib(TRK Kinase Inhibitor)	Solid tumors	Resistant	A	YES	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf	only alteration type		SOLID
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification + KRAS wildtype + NRAS wildtype	Tucatinib(ERBB2 inhibitor);Trastuzumab(ERBB2 inhibitor) 	Colorectal adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer	only gene		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Atezolizumab(PD-L1 blocking antibody);Vemurafenib(BRAF inhibitor);Cobimetinib(MEK inhibitor) 	Cutaneous melanoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Solid tumors	Responsive	A	YES	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid	only alteration type		SOLID
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Lower grade glioma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation	only alteration type		LGG
input02	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Anaplastic large cell lymphoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-children-and-young-adults-relapsed-or-refractory-systemic-anaplastic-large	only gene		ALCL
input02	FGFR2 MUT* (--)	FGFR2 fusion	Futibatinib(pan-FGFR inhibitor)	Intrahepatic cholangiocarcinoma	Responsive	A	NO	FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma	only gene		IHCH
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Olaparib(PARP inhibitor);Abiraterone(Hormone therapy);Prednisone(Steroid)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration	only alteration type		PRAD
input02	ATR MUT* (--)	ATR oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input02	CDK12 MUT* (--)	CDK12 oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input02	FANCA MUT* (--)	FANCA oncogenic mutation	Talazoparib(PARP inhibitor);Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate	only alteration type		PRAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab deruxtecan-nxki(Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer	only gene		BRCA
input02	NRAS wildtype	NRAS wildtype	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf	complete		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf	only alteration type		CM
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	A	NO	NCCN  https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
input02	BTK MUT* (F386)	BTK (C481S)	Ibrutinib(BTK inhibitor)	Chronic lymphocytic leukemia	Resistant	A	NO	PMID: 28418267	only alteration type		CLL
input02	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc	only gene		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf	only gene		BRCA
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	only alteration type		PLEN
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 inhibitor) + Carboplatin-Taxol(Chemotherapy)	Uterus	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf	only gene		U
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Trametinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF oncogenic mutation (except V600 mutation)	Cobimetinib(MEK inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input02	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (L858R)	Erlotinib(EGFR inhibitor 1st gen);Ramucirumab(VEGFR2 antagonist)	Non-small cell lung	Responsive	A	NO	FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	only alteration type		NSCLC
input02	ERBB2 (G346D)	ERBB2 oncogenic mutation	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	complete		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF(V600E)	Vemurafenib(BRAF inhibitor)	Langerhans cell histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Dabrafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf	only alteration type		HISEC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Pertuzumab(ERBB2 inhibitor)+ Trastuzumab(ERBB2 inhibitor) 	Billiary tract	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf	only gene		BT
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf	only alteration type		COREAD
input02	PDGFRA MUT* (--)	PDGFRA oncogenic mutations (excluding D842V + exon 18 inframe mutations)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Responsive	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V + exon 18 mutations	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	A	NO	NCCN guidelines https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf	only alteration type		GIST
input02	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	FDA  https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor	only gene		IM
input02	ALK MUT* (--)	ALK fusion	Alectinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input02	ALK MUT* (--)	ALK fusion	Brigatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input02	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input02	ALK MUT* (--)	ALK fusion	Lorlatinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf	only gene		IM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Hairy-Cell leukemia	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf	only alteration type		HCL
input02	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input02	MET MUT* (--)	MET amplification	Capmatinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input02	MET MUT* (--)	MET amplification	Tepotinib(MET inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input02	MET MUT* (--)	MET exon 14 skipping mutations	Crizotinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	ROS1 MUT* (F383)	ROS1 fusion	Ceritinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input02	ROS1 MUT* (F383)	ROS1 fusion	Lorlatinib(ALK inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Gefitinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 20 inframe insertions	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Resistant	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Rucaparib(PARP inhibitor)	Pancreas adenocarcinoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	only alteration type		PAAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Non-small cell lung	Responsive	A	NO	FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF(V600)	Vemurafenib(BRAF inhibitor)	Erdheim-Chester histiocytosis	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf	only alteration type		HISEC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Dabrafenib(BRAF inhibitor )+ Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Encorafenib(BRAF inhibitor) + Binimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600 (excluding V600E, V600K)	Vemurafenib(BRAF inhibitor) + Cobimetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf	only alteration type		CM
input02	EGFR MUT* (--)	EGFR (S768I,L861Q,G719)	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	NCCN https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Dacomitinib(EGFR inhibitor)	Non-small cell lung	Responsive	A	NO	FDA: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer-0	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 19 inframe deletions	Osimertinib(EGFR inhibitor 3rd gen)	Non-small cell lung	Responsive	A	NO	FDA  https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf	only alteration type		NSCLC
input02	AKT1 MUT* (E117-)	AKT1 (Q79K,E17K)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265152	only alteration type		CM
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	AKT inhibitors	Any cancer type	Responsive	D	YES	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)	only alteration type		CANCER
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E,G469A)	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:22773810	only alteration type		LUAD
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	non-allosteric AKT inhibitors	Any cancer type	Responsive	C	YES	ENA 2015 (abstract B109);PMID:28489509	only alteration type		CANCER
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only alteration type		HNSC
input02	AKT1 MUT* (E117-)	AKT1 (H238Y)	Everolimus(MTOR inhibitor)	Fibrous histiocytoma	Responsive	C	NO	ASCO 2015 (abstr 11010)	only alteration type		FH
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
input02	AKT2 MUT* (--), AKT2 (E279K)	AKT2 amplification	MK2206(Allosteric AKT inhibitor)	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 373)	only gene		CANCER
input02	ALK MUT* (--)	ALK fusion	ALK inhibitor + IGF1R inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25173427	only gene		LUAD
input02	ALK MUT* (--)	ALK fusion	ALK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:26301689	only gene		LUAD
input02	ALK MUT* (--)	ALK fusion	ALK inhibitor + SRC inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:25394791	only gene		LUAD
input02	ALK MUT* (--)	ALK fusion	ALK inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560	only gene		COREAD
input02	ALK MUT* (--)	ALK fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23553849	only gene		LUAD
input02	ALK MUT* (--)	ALK fusion	novel ALK inhibitors	Lung adenocarcinoma	Responsive	C	NO	PMID:23639470	only gene		LUAD
input02	ALK MUT* (--)	ALK (F1174L)	novel ALK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:24327273	only alteration type		LUAD
input02	ALK MUT* (--)	ALK amplification	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only gene		LUAD
input02	ALK MUT* (--)	ALK (E1408V)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
input02	ALK MUT* (--)	ALK (L1196M)	Brigatinib(Pan-TK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9065)	only alteration type		LUAD
input02	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Colorectal adenocarcinoma, Inflammatory myofibroblastic	Responsive	C	NO	PMID:26633560;PMID:26933125;PMID:27742657	only gene		COREAD, IM
input02	ALK MUT* (--)	ALK fusion	Ceritinib(ALK inhibitor)	Hematologic malignancies	Responsive	C	NO	NCT02186821	only gene		HEMATO
input02	CTNNB1 MUT* (--)	CTNNB1 oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Resistant	D	NO	PMID:23539443	only alteration type		COREAD
input02	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Lymphoma, Glioblastoma	Responsive	C	NO	PMID:24491302;NCT02270034	only gene		LY, GB
input02	ALK MUT* (--)	ALK fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic, Thyroid carcinoma	Responsive	C	NO	PMID:20979472;PMID:24687827	only gene		IM, THCA
input02	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
input02	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 1st gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
input02	EGFR MUT* (--)	EGFR (D761Y)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	C	NO	PMID:19680293	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 1st gens	Non-small cell lung	Resistant	B	NO	PMID:19680293	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
input02	ALK MUT* (--)	ALK (F856S,A348D)	Crizotinib(ALK inhibitor)	Acute myeloid leukemia	Responsive	D	NO	PMID:26032424	only alteration type		AML
input02	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 2nd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
input02	ALK MUT* (--)	ALK (L1198F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26698910	only alteration type		LUAD
input02	ALK MUT* (--)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib(ALK inhibitor)	Glioma	Responsive	D	NO	PMID:22072639	only alteration type		G
input02	ALK MUT* (--)	ALK fusion	Entrectinib(Pan-TK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26633560;PMID:26933125	only gene		COREAD
input02	ALK MUT* (--)	ALK (C1156Y)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:27401242	only alteration type		LUAD
input02	APC MUT* (--)	APC oncogenic mutation	Tankyrase inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:22440753;PMID:23539443	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 2nd gens	Non-small cell lung	Resistant	B	NO	PMID:22452896	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR inframe deletion (30-336)	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:19204207	only alteration type		G
input02	EGFR MUT* (--)	EGFR amplification	EGFR inhibitor 3rd gens	Glioma	No Responsive	C	NO	PMID:16282176;PMID:16278407	only gene		G
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR amplification	AR inhibitor next gens	Prostate adenocarcinoma	Responsive	D	NO	PMID:23589709;PMID:21859989	only gene		PRAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	EGFR inhibitors	Lung adenocarcinoma	Resistant	D	NO	PMID:22956644	only gene		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22586653;PMID:23348520	only gene		COREAD
input02	FBXW7 MUT* (--), FBXW7 MUT* (--)	FBXW7 oncogenic mutation	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only alteration type		CANCER
input02	AR MUT* (RQ85-86R), AR MUT* (--), AR MUT* (RQ85-86R), AR MUT* (--)	AR (F877L) + AR (T878A)	Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Responsive	D	NO	PMID:27196756	only alteration type		PRAD
input02	FBXW7 MUT* (--), FBXW7 MUT* (--)	FBXW7 deletion	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
input02	FGFR2 MUT* (--), FGFR2 MUT* (--)	FGFR2 (N549H,V564F,K659M,L617V,K641R,R565A) + FGFR2 fusion	FGFR inhibitors	Cholangiocarcinoma	Resistant	C	NO	PMID:28034880;ASCO 2017 (abstr 2500)	only gene		CH
input02	ARID1A MUT* (P16-)	ARID1A oncogenic mutation	ATR inhibitors	Any cancer type	Responsive	D	YES	PMID:27958275	only alteration type		CANCER
input02	ARID1A MUT* (P16-)	ARID1A oncogenic mutation	EZH2 inhibitors	Ovary	Responsive	D	NO	PMID:25686104	only alteration type		OV
input02	ARID1A MUT* (P16-)	ARID1A oncogenic mutation	PARP inhibitors	Any cancer type	Responsive	D	YES	PMID:26069190	only alteration type		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (V555M)	FGFR inhibitors	Myeloma	Resistant	D	NO	PMID:22869148	only alteration type		MYMA
input02	ATR MUT* (--)	ATR oncogenic mutation	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only alteration type		OV, CANCER
input02	ATR MUT* (--)	ATR deletion	Olaparib(PARP inhibitor)	Ovary, Any cancer type	Responsive	D	YES	PMID:23548269	only gene		OV, CANCER
input02	ATR MUT* (--)	ATR oncogenic mutation	Temozolomide(Chemotherapy)	Glioma	Responsive	D	NO	PMID:23960094	only alteration type		G
input02	AURKA MUT* (--), AURKA MUT* (--)	AURKA amplification	AURK inhibitors	Prostate adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:22302096;PMID:22389870	only gene		PRAD, CANCER
input02	IGF2 MUT* (--)	IGF2 amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:25632036	only gene		COREAD
input02	BCL2 MUT* (--)	BCL2 amplification	BCL2 inhibitors	Lymphoma	Responsive	D	NO	PMID:22649144	only gene		LY
input02	BCOR MUT* (E811K)	BCOR oncogenic mutation	Enzastaurin(PKCb inhibitor)	Stomach	Responsive	D	NO	PMID:27397505	only alteration type		ST
input02	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27903500	only alteration type		COREAD
input02	JAK1 MUT* (--)	JAK1 oncogenic mutation	PD1 inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:27433843	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + CDK2/4 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22997239	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:28363909	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + HSP90 inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22351686	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + MEK inhibitors	Thyroid	Responsive	C	NO	ASCO 2013 (abstr 9029)	only alteration type		TH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	BRAF inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 9072)	only gene		LUAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitor + PI3K pathway inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22389471;PMID:21156289	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (L597R)	BRAF inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:23715574	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Glioma	Responsive	D	NO	PMID:22038996;PMID:22586120	only alteration type		G
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	BRAF inhibitors	Ovary	Responsive	C	NO	PMID:22608338	only alteration type		OV
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23614898;PMID:22997239	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (G469A)	ERK inhibitors	Head an neck squamous	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		HNSC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (L485W)	ERK inhibitors	Billiary tract	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		BT
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	ERK inhibitors	Lung adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2508)	only alteration type		LUAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Thyroid	Responsive	C	NO	PMID:22241789	only alteration type		TH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	MEK inhibitors	Ovary	Responsive	D	NO	PMID:19018267	only alteration type		OV
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Pan-RAF inhibitors	Any cancer type	Responsive	D	YES	PMID:26732095	only alteration type		CANCER
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Pan-RAF inhibitors	Cutaneous melanoma	Responsive	C	NO	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	MEK inhibitors(Trametinib,etc)	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:24727320;PMID:24345920;PMID:20526349	only gene		LUAD, CM, PRAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (K601R,L597R,V600R)	MEK inhibitors(Trametinib,etc)	Cutaneous melanoma	Responsive	C	NO	PMID:23248257;PMID:22805292;PMID:23248257	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Lung adenocarcinoma, Thyroid	Responsive	C	NO	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216	only alteration type		LUAD, TH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib(BRAF inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:23470635;PMID:22608338	only alteration type		GIST
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600R)	Dabrafenib(BRAF inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23237741	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:26392102;ASCO 2015 (abstr 8006)	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Dabrafenib + Trametinib(BRAF inhibitor + MEK inhibitor)	Neuroendocrine	Responsive	C	NO	PMID:27048246	only alteration type		NEU
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (G466V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:22649091	only alteration type		LUAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (Y472C)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:22649091	only alteration type		LUAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Irinotecan + Vemurafenib + Cetuximab(TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27729313	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + BYL719(EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2014 (abstr 11LBA)	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Panitumumab + Dabrafenib + Trametinib(EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	PLX4720(BRAF inhibitor)	Malignant astrocytoma	Responsive	D	NO	PMC3638050	only alteration type		MA
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Selumetinib(MEK inhibitor)	Ovary	Responsive	C	NO	PMID:26324360	only gene		OV
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Selumetinib(MEK inhibitor)	Pediatric glioma	Responsive	C	NO	NCT01089101	only alteration type		PG
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	Responsive	D	NO	PMID:238900088;PMID:20526349;PMID:24727320	only gene		CM, LUAD, PRAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (D594G,G469E)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:18794803	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	Responsive	C	NO	PMID:22743296;PMID:22621641;PMID:23612012	only alteration type		LUAD, HCL, MYMA
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Malignant astrocytoma	Responsive	C	NO	PMID:22586120	only alteration type		MA
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Vemurafenib(BRAF inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:22608338;PMID:20818844;PMID:23489023	only alteration type		THCA
input02	BRAF MUT* (--), BRAF MUT* (--), EGFR MUT* (--)	BRAF (G469A) + EGFR oncogenic mutation	EGFR TK inhibitor + MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:22773810	only alteration type		LUAD
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitor + Chemotherapys	Ovary	Responsive	C	NO	PMID:22307137;ASCO 2012 (abstr 1009)	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	PMID:26997480	only alteration type		CM
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	PARP inhibitors(Olaparib,etc)	Breast adenocarcinoma	Responsive	C	NO	PMID:20609467	only alteration type		BRCA
input02	BRCA2 MUT* (--)	BRCA2 deletion	PARP inhibitors(Olaparib,etc)	Ovary	Responsive	D	NO	PMID:22392482	only gene		OV
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:25847936	only alteration type		BRCA
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Ovary	Responsive	B	NO	PMID:22406760;PMID:22711857	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Platinum Agent(Chemotherapy)	Pancreas	Responsive	C	NO	PMID:25719666	only alteration type		PA
input02	BRCA2 MUT* (--)	BRCA2 oncogenic mutation	Veliparib + Cisplatin(PARP inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:26801247	only alteration type		BRCA
input02	CBL MUT* (H36-), CBL MUT* (--), CBL MUT* (--)	CBL (Y371H,C384R)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:23696637	only alteration type		MDPS
input02	CBL MUT* (H36-), CBL MUT* (--), CBL MUT* (--)	CBL (Y371H,C384R)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:23696637	only alteration type		MDPS
input02	CDH1 (AL10-11A)	CDH1 oncogenic mutation	Bicalutamide(AR inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27397505	complete		BRCA
input02	CDK12 MUT* (--)	CDK12 oncogenic mutation	PARP inhibitors	Ovary	Responsive	D	NO	PMID:24240700;PMID:24554720	only alteration type		OV
input02	CDK12 MUT* (--)	CDK12 amplification	PARP inhibitors	Ovary	Responsive	D	NO	PMID:24240700;PMID:24554720	only gene		OV
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	complete		CM
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A oncogenic mutation	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	complete		G, CANCER
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A deletion	CDK4/6 inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr 2500)	only gene		CM
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A deletion	CDK4/6 inhibitors	Glioma, Any cancer type	Responsive	D	YES	PMID:22471707;PMID:22586120;PMID:22711607	only gene		G, CANCER
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A oncogenic mutation	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	complete		CANCER
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A deletion	Ilorasertib(AURKA-VEGF inhibitor)	Any cancer type	Responsive	C	YES	NCT02478320	only gene		CANCER
input02	CTNNB1 MUT* (--)	CTNNB1 (H36Y,S37C,S37Y,D32V)	Everolimus + Letrozole(MTOR inhibitor + Hormonal therapy)	Endometrium	Responsive	C	NO	PMID:25624430	only alteration type		ED
input02	MCL1 MUT* (ED171-172D)	MCL1 amplification	Tubulin inhibitors	Any cancer type	Resistant	D	YES	PMID:21368834	only gene		CANCER
input02	MET MUT* (--)	MET amplification	EGFR inhibitor 1st gens	Non-small cell lung, Colorectal adenocarcinoma	Resistant	C	NO	PMID:22189054;PMID:23729478	only gene		NSCLC, COREAD
input02	MET MUT* (--)	MET amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Resistant	C	NO	PMID:23729478	only gene		COREAD
input02	MET MUT* (--)	MET (D1246V)	MET inhibitors	Lung adenocarcinoma	Resistant	C	NO	PMID:27694386	only alteration type		LUAD
input02	MET MUT* (--), EGFR MUT* (--)	MET amplification + EGFR oncogenic mutation	EGFR TK inhibitors	Lung adenocarcinoma	Resistant	C	NO	ASCO 2015 (abstr 8089)	only gene		LUAD
input02	MITF MUT* (--)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
input02	MITF MUT* (--)	MITF amplification	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMID:24265153	only gene		CM
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only alteration type		NB
input02	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens	Lung	Responsive	C	NO	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)	only alteration type		L
input02	EGFR MUT* (--)	EGFR amplification	EGFR inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26763254	only gene		HNSC
input02	EGFR MUT* (--)	EGFR amplification	EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	B	NO	PMID:18794099;PMID:17664472	only gene		COREAD
input02	EGFR MUT* (--)	EGFR exon 19 insertions	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
input02	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	EGFR TK inhibitors	Lung	Responsive	B	NO	PMID:22753918	only alteration type		L
input02	EGFR MUT* (--)	EGFR exon 19 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
input02	EGFR MUT* (--)	EGFR exon 20 insertions	HSP90 inhibitors	Lung	Responsive	C	NO	ASCO 2014 (abstr 8015)	only alteration type		L
input02	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
input02	EGFR MUT* (--)	EGFR (T790M)	HSP90 inhibitors	Lung	Responsive	C	NO	ESMO 2012 (abstr 4380)	only alteration type		L
input02	EGFR MUT* (--)	EGFR exon 19 insertions	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
input02	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	MEK inhibitor(alone or in combination)s	Lung	Responsive	D	NO	PMID:23102728	only alteration type		L
input02	EGFR MUT* (--)	EGFR (S492R)	novel EGFR mAb inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	PMID:25962717	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR (T790M)	EGFR inhibitor 3rd gens(Rociletinib,HM61713,etc)	Non-small cell lung	Responsive	B	NO	NCT02322281	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib(ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung	Responsive	B	NO	PMID:22753918;PMID:25589191	only alteration type		L
input02	NF1 MUT* (--)	NF1 deletion	Retinoic Acids	Neuroblastoma	Resistant	D	NO	PMID:20655465	only gene		NB
input02	EGFR MUT* (--)	EGFR exon 19 insertions	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
input02	EGFR MUT* (--)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	ESMO 2012 (abstr 1289)	only alteration type		L
input02	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Cetuximab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:25074459	only alteration type		L
input02	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Nimotuzumab(ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	Lung	Responsive	C	NO	PMID:26667485	only alteration type		L
input02	EGFR MUT* (--)	EGFR (P546S)	Cetuximab(EGFR mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:23578570	only alteration type		HNC
input02	EGFR MUT* (--)	EGFR (P753S)	Cetuximab + Sirolimus(EGFR mAb inhibitor + MTOR inhibitor)	Head an neck	Responsive	C	NO	PMID:24934779	only alteration type		HNC
input02	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Non-small cell lung	Responsive	C	NO	PMID:27102076	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR-RAD51 fusion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:27102076	only gene		L
input02	EGFR MUT* (--)	EGFR exon 19 insertions	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:22190593	only alteration type		L
input02	EGFR MUT* (--)	EGFR inframe insertion (769-770)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740;PMID:23328547	only alteration type		L
input02	EGFR MUT* (--)	EGFR (A289V,R108K,G598V,T263P)	Erlotinib(EGFR inhibitor 1st gen)	Glioma	Responsive	D	NO	PMID:17177598	only alteration type		G
input02	EGFR MUT* (--)	EGFR (K757R,E746G)	Erlotinib(EGFR inhibitor 1st gen)	Lung	Responsive	C	NO	PMID:26773740	only alteration type		L
input02	PDGFRA MUT* (--)	PDGFRA amplification	PDGFR inhibitors	Glioma	No Responsive	D	NO	PMID:23544171	only gene		G
input02	PIK3CA MUT* (--)	PIK3CA (E545*)	BRAF inhibitors	Cutaneous melanoma	Resistant	C	NO	PMC3936420	only alteration type		CM
input02	PIK3CA MUT* (--)	PIK3CA amplification	PI3K pathway inhibitors	Breast adenocarcinoma	Resistant	D	NO	PMID:24366379	only gene		BRCA
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Lung	No Responsive	C	NO	ASCO 2017 (abstr 9054)	only alteration type		L
input02	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Endometrium	Responsive	B	NO	PMID:24950987	only gene		ED
input02	EGFR MUT* (--)	EGFR (E690K)	Lapatinib(ERBB2 inhibitor)	Endometrium	Responsive	C	NO	PMID:22885469	only alteration type		ED
input02	EGFR MUT* (--)	EGFR exon 19 deletions	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Responsive	C	NO	NCT02465060	only alteration type		L
input02	EGFR MUT* (--)	EGFR (S492R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:22270724	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR inframe deletion (6-273)	Rindopepimut(Vaccine)	Glioblastoma	Responsive	B	NO	NCT01480479	only alteration type		GB
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	ERBB2 inhibitor + CDK4/6 inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:26977878	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 proximal exon 20	ERBB2 inhibitors(Afatinib,Lapatinib,Neratinib,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 proximal exon 20	ERBB2 mAb inhibitors(Trastuzumab,etc)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (V659E,S310F)	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Lung	Responsive	C	NO	ASCO 2017 (abstr 8510)	only alteration type		L
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Stomach	Responsive	C	NO	AACR 2014 (abstr CT228)	only gene		ST
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	B	NO	PMID:20142587;PMID:22418700;PMID:23632474	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Bladder	Responsive	C	NO	PMID:27044931	only gene		BLCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 proximal exon 20	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (T798I)	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Breast adenocarcinoma	Responsive	D	NO	PMID:28274957	only alteration type		BRCA
input02	ERBB2 (G346D)	ERBB2 oncogenic mutation	Dacomitinib(Pan ERBB inhibitor)	Non-small cell lung	Responsive	C	NO	PMID:25899785	complete		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (V659E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma, Lung adenocarcinoma	Responsive	C	NO	PMID:23950206	only alteration type		BRCA, LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 proximal exon 20	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Lapatinib + Chemotherapy(ERBB2 inhibitor + Chemotherapy)	Stomach	Responsive	C	NO	PMID:25694417;NCT02015169	only gene		ST
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
input02	ERBB2 (G346D)	ERBB2 oncogenic mutation	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	complete		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (K753E)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:27697991	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:23220880	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 proximal exon 20	Neratinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (L869R)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:28274957	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (S310,L755,V777)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Neratinib(ERBB2 inhibitor)	Any cancer type	Responsive	C	YES	AACR 2017 (abstr CT001)	only alteration type		CANCER
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:24960402	only gene		ST
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Pertuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
input02	ERBB2 (G346D)	ERBB2 oncogenic mutation	Tensirolimus(MTOR inhibitor)	Lung adenocarcinoma	Responsive	C	NO	ESMO 2014 (abstr LBA39_PR)	complete		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Billiary tract	Responsive	C	NO	PMID:26022204	only gene		BT
input02	STK11 MUT* (--)	STK11 oncogenic mutation	BET inhibitors	Lung	Resistant	D	NO	PMID:23129625;PMID:24045185	only alteration type		L
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Head an neck	Responsive	C	NO	PMID:21380780	only gene		HNC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Ovary	Responsive	C	NO	PMID:20003286;PMID:12525520	only gene		OV
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Any cancer type	Responsive	D	YES	PMID:23220880;PMID:22908275	only alteration type		BRCA, CANCER
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Trastuzumab(ERBB2 mAb inhibitor)	Any cancer type	Responsive	D	YES	PMID:22908275	only alteration type		CANCER
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (G776L)	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:16775247	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 proximal exon 20	Trastuzumab(ERBB2 mAb inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:26598547;ASCO 2017 (abstr 9071)	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Ado-Trastuzumab Emtansine(ERBB2 mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	http://ascopubs.org/doi/full/10.1200/PO.16.00055	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab + Everolimus + Chemotherapy(ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	C	NO	PMID:21107682;PMID:20975068	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab + HSP90 inhibitor(ERBB2 mAb inhibitor + HSP90 inhibitor)	Breast adenocarcinoma	Responsive	C	NO	PMID:21558407	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab + Lapatinib(ERBB2 mAb inhibitor + ERBB2 inhibitor)	Endometrium	Responsive	D	NO	PMID:25294905	only gene		ED
input02	ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (E317K,E452K,R544W,R393W,E872K)	Lapatinib(ERBB2 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:19718025	only alteration type		CM
input02	ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 fusion	Lapatinib + Afatinib(ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	MDM2 inhibitors	Liposarcoma	Resistant	C	NO	PMID:23084521;ASCO 2015 (abstr 10564)	complete		LIP
input02	ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 (H809G)	ERBB2 inhibitors(Lapatinib,etc)	Breast adenocarcinoma	Resistant	C	NO	PMID:26530965	only alteration type		BRCA
input02	FANCA MUT* (--)	FANCA oncogenic mutation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
input02	FANCA MUT* (--)	FANCA deletion	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only gene		PRAD
input02	FANCC MUT* (--), FANCC MUT* (--), FANCC MUT* (F318L)	FANCC oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
input02	FANCC MUT* (--), FANCC MUT* (--), FANCC MUT* (F318L)	FANCC deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
input02	FAT1 (Q2845*), FAT1 (G1774E), FAT1 (T1773X)	FAT1 oncogenic mutation	BET inhibitors	Head an neck squamous	Responsive	D	NO	PMID:27397505	complete		HNSC
input02	FBXW7 MUT* (--), FBXW7 MUT* (--)	FBXW7 oncogenic mutation	Steroids	Acute lymphoblastic leukemia	Responsive	B	NO	PMID:20861909	only alteration type		ALL
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Abemaciclib(CDK4/CDK6 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:27217383	complete		BRCA
input02	FBXW7 MUT* (--), FBXW7 MUT* (--)	FBXW7 deletion	Sirolimus(MTOR inhibitor)	Colorectal adenocarcinoma	Responsive	D	NO	PMID:23558291	only gene		COREAD
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR amplification	Abiraterone(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:26537258	only gene		PRAD
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR (L702H,T878A)	Abiraterone(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:26537258	only alteration type		PRAD
input02	FGFR2 MUT* (--)	FGFR2 fusion	FGFR inhibitors	Billiary tract	Responsive	C	NO	ASCO 2016 (abstr 109)	only gene		BT
input02	FGFR2 MUT* (--)	FGFR2 inframe insertion (A266),inframe insertion (S267)	FGFR inhibitors	Lung	Responsive	D	NO	PMID:26048680	only alteration type		L
input02	FGFR2 MUT* (--)	FGFR2 amplification	FGFR inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2508)	only gene		ST
input02	FGFR2 MUT* (--)	FGFR2 amplification	FGFR inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:25193991	only gene		BRCA
input02	FGFR2 MUT* (--)	FGFR2 (S252W,N550K)	FGFR inhibitors	Endometrium	Responsive	D	NO	PMID:18552176;PMID:22238366;PMID:23002168	only alteration type		ED
input02	FGFR2 MUT* (--)	FGFR2 (V565I)	FGFR inhibitors	Endometrium	Responsive	D	NO	ENA 2014 (abstr 381)	only alteration type		ED
input02	FGFR2 MUT* (--)	FGFR2 (W290C,S320C,K660N)	FGFR inhibitors	Lung squamous cell	Responsive	D	NO	PMID:23786770;PMID:25035393	only alteration type		LUSC
input02	FGFR2 MUT* (--)	FGFR2 fusion	FGFR inhibitors	Colorectal adenocarcinoma	Responsive	C	NO	ASCO 2017 (abstr 2500)	only gene		COREAD
input02	ALK MUT* (--)	ALK (I1171T)	Alectinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:25228534	only alteration type		LUAD
input02	FGFR2 MUT* (--)	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Endometrium	Responsive	D	NO	PMID:23908597	only alteration type		ED
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Glioma	Responsive	C	NO	PMID:26324363	only gene		G
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 oncogenic mutation	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:27870574	only alteration type		BLCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (K650,Y373C)	FGFR inhibitors	Myeloma	Responsive	D	NO	PMID:16091734;PMID:20439987;PMID:22869148	only alteration type		MYMA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (S249C,G691R)	FGFR inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:27998968	only alteration type		LUAD
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR (F877L)	Arn-509(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:23779130	only alteration type		PRAD
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 fusion	FGFR inhibitors	Bladder	Responsive	C	NO	PMID:26324363;ASCO 2017 (abstr 2500)	only gene		BLCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (K650)	Bortezomib(Proteasome inhibitor)	Myeloma	Responsive	D	NO	PMID:19331127;PMID:21273588	only alteration type		MYMA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3-TACC3 fusion	FGFR inhibitors(,etc)	Non-small cell lung	Responsive	D	NO	PMID:25294908	only gene		NSCLC
input02	FGFR4 MUT* (--)	FGFR4 (N535,V550)	FGFR inhibitors	Rhabdomyosarcoma	Responsive	D	NO	PMID:19809159;PMID:24124571	only alteration type		RHBDS
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (Y373C)	Bortezomib(Proteasome inhibitor)	Myeloma	Resistant	D	NO	PMID:19331127;PMID:21273588	only alteration type		MYMA
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only alteration type		PLEN
input02	NF1 MUT* (--)	NF1 deletion	Cediranib(ALK inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	NCT00326872	only gene		PLEN
input02	ALK MUT* (--)	ALK (G1123S)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:26134233	only alteration type		LUAD
input02	ROS1 MUT* (F383)	ROS1 (S1986Y,S1986F)	Ceritinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
input02	GNAQ (A18V)	GNAQ (Q209)	HDAC inhibitors	Cutaneous melanoma	Responsive	D	NO	NCT01587352	only alteration type		CM
input02	GNAQ (A18V)	GNAQ (Q209)	PI3K pathway inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22733540;PMID:22808163	only alteration type		CM
input02	GNAQ (A18V)	GNAQ (Q209)	PKC inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:22653968;PMID:22253748	only alteration type		CM
input02	GNAQ (A18V)	GNAQ (Q209)	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Responsive	C	NO	ASCO 2013 (abstr CRA9003)	only alteration type		CM
input02	GNAS MUT* (--), GNAS MUT* (--), GNAS MUT* (--)	GNAS (R201)	JAK inhibitors	Any cancer type	Responsive	D	YES	PMID:21835143	only alteration type		CANCER
input02	HDAC2 MUT* (--), HDAC2 MUT* (--)	HDAC2 biallelic inactivation	Olaparib(PARP inhibitor)	Prostate adenocarcinoma	Responsive	C	NO	PMID:26510020	only alteration type		PRAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR (S464L,G465R,I491M)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	D	NO	PMID:25623215	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR (S492R,G465R,R451C,K467T)	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827	only alteration type		COREAD
input02	INPP4B MUT* (--)	INPP4B oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only alteration type		BRCA
input02	INPP4B MUT* (--)	INPP4B deletion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:23551093	only gene		BRCA
input02	JAK1 MUT* (--)	JAK1 (S646F;R683)	Ruxolitinib(JAK inhibitor)	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:22955920;PMID:18805579	only alteration type		ALL
input02	JAK3 MUT* (S789)	JAK3 (A572V,A573V)	JAK inhibitors	Lymphoma	Responsive	D	NO	PMID:22705984	only alteration type		LY
input02	JAK3 MUT* (S789)	JAK3 (R657Q,I87T,Q501H)	JAK inhibitors	Megakaryoblastic leukemia	Responsive	D	NO	PMID:18397343	only alteration type		MKB
input02	KIT MUT* (P166L)	KIT mutation in exon 11	HSP90 inhibitors	Gastrointestinal stromal	Responsive	C	NO	PMID:22898035	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT mutation in exon 9 or 17	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:21737509	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Dasatinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:19671763	only alteration type		CM
input02	KIT MUT* (P166L)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Systemic mastocytosis	Responsive	C	NO	PMID:18559612	only alteration type		SM
input02	KIT MUT* (P166L)	KIT (D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	C	NO	PMID:18986703	only alteration type		AML
input02	KIT MUT* (P166L)	KIT (D816Y,D816F,D816V)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Any cancer type	Responsive	D	YES	PMID:16397263	only alteration type		CANCER
input02	KIT MUT* (P166L)	KIT (N822K)	Dasatinib(BCR-ABL inhibitor 2nd gen)	Acute myeloid leukemia	Responsive	D	NO	PMID:23149070	only alteration type		AML
input02	KIT MUT* (P166L)	KIT inframe deletion (416-422),inframe insertion (416-422)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Acute myeloid leukemia	Responsive	D	NO	PMID:15618474	only alteration type		AML
input02	KIT MUT* (P166L)	KIT inframe deletion (V560)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	NO	PMID:15201427	only alteration type		THYM
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	Cetuximab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:19223544;PMID:20619739	only alteration type		COREAD
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Cisplatin(Chemotherapy)	Female germ cell tumor, Male germ cell tumor	Resistant	C	NO	PMID:27646943	complete		FGCT, MGCT
input02	ALK MUT* (--)	ALK inframe insertion (1151T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only alteration type		LUAD
input02	KIT MUT* (P166L)	KIT (D820Y)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:23775962	only alteration type		CM
input02	ALK MUT* (--)	ALK oncogenic mutation	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:22235099	only gene		NSCLC
input02	KIT MUT* (P166L)	KIT (Y553N)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Thymic	Responsive	C	NO	PMID:21969494	only alteration type		THYM
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:22068222;PMID:25695690	only alteration type		CM
input02	KIT MUT* (P166L)	KIT mutation in exon 17	Nilotinib(BCR-ABL inhibitor 2nd gen)	Gastrointestinal stromal	Responsive	C	NO	PMID:22119758;PMID:21456006	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT (D820Y)	Nilotinib(BCR-ABL inhibitor 2nd gen)	Cutaneous melanoma	Responsive	C	NO	PMID:25695690	only alteration type		CM
input02	KIT MUT* (P166L)	KIT (788-828,829-860,550-592)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT (A829P,V654A,T670I)	Ponatinib(BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:25239608	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT inframe deletion (577-579)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	NO	PMID:20970876	only alteration type		THYM
input02	KIT MUT* (P166L)	KIT mutation in exon 9 or 11	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	C	NO	PMID:22270258	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT (550-592,627-664,788-828,829-860)	Sorafenib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	C	NO	PMID:18936790;PMID:20372153	only alteration type		CM
input02	KIT MUT* (P166L)	KIT mutation in exon 17	Sorafenib(Pan-TK inhibitor)	Gastrointestinal stromal	Responsive	D	NO	PMID:23840364	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT (D820E)	Sorafenib(Pan-TK inhibitor)	Thymic	Responsive	C	NO	PMID:19461405	only alteration type		THYM
input02	ALK MUT* (--)	ALK amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784	only gene		LUAD
input02	KIT MUT* (P166L)	KIT mutation in exon 9,11,13,14 or 17	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	Responsive	B	NO	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812	only alteration type		CM
input02	ALK MUT* (--)	ALK (C1156Y,L1196M)	Crizotinib(ALK inhibitor)	Non-small cell lung	Resistant	C	NO	PMID:20979473	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK (F1174L)	Crizotinib(ALK inhibitor)	Glioma	Resistant	D	NO	PMID:22072639	only alteration type		G
input02	KIT MUT* (P166L)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	NO	PMID:19861435	only alteration type		THYM
input02	KIT MUT* (P166L)	KIT (H697Y)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	D	NO	PMID:19861435	only alteration type		THYM
input02	KIT MUT* (P166L)	KIT (Y553N)	Sunitinib(Pan-TK inhibitor)	Thymic	Responsive	C	NO	PMID:23375402	only alteration type		THYM
input02	ALK MUT* (--)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:22277784;PMID:25228534	only alteration type		LUAD
input02	MET MUT* (--)	MET (Y1230C,Y1235D)	Crizotinib(ALK inhibitor)	Any cancer type	Resistant	D	YES	PMID:17483355	only alteration type		CANCER
input02	ROS1 MUT* (F383)	ROS1 (G2032R)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:23724914;PMID:25688157	only alteration type		LUAD
input02	ROS1 MUT* (F383)	ROS1 (S1986Y,S1986F)	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27401242	only alteration type		LUAD
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only alteration type		L
input02	NF1 MUT* (--)	NF1 deletion	Dasatinib(BCR-ABL inhibitor 2nd gen)	Lung	Resistant	D	NO	PMID:24296828	only gene		L
input02	FGFR2 MUT* (--)	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	Dovitinib(FGFR inhibitor)	Endometrium	Resistant	D	NO	PMID:23908597	only alteration type		ED
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR (F877L)	Enzalutamide(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:23779130	only alteration type		PRAD
input02	EGFR MUT* (--)	EGFR amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	ASCO2015(abstre19028)	only gene		L
input02	EGFR MUT* (--)	EGFR (S720)	Erlotinib(EGFR inhibitor 1st gen)	Lung	No Responsive	C	NO	PMID:26773740	only alteration type		L
input02	IGF1R MUT* (--), IGF1R MUT* (--), IGF1R MUT* (--)	IGF1R amplification	Erlotinib(EGFR inhibitor 1st gen)	Lung adenocarcinoma	Resistant	D	NO	PMID:24458568	only gene		LUAD
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only alteration type		L
input02	NF1 MUT* (--)	NF1 deletion	Erlotinib(EGFR inhibitor 1st gen)	Lung	Resistant	D	NO	PMID:24535670	only gene		L
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (F2108L)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Resistant	C	NO	PMID:25295501	only alteration type		THCA
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	NCT01365468	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	Everolimus + Bevacizumab(MTOR inhibitor + VEGFR mAb inhibitor)	Malignant peripheral nerve sheat tumor	No Responsive	C	NO	ASCO 2016 (abstr 11053)	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only alteration type		G
input02	NF1 MUT* (--)	NF1 deletion	Everolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	No Responsive	C	NO	PMID:24634382	only gene		G
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR (T878A)	Flutamide(AR inhibitor)	Prostate adenocarcinoma	Resistant	C	NO	PMID:2260966	only alteration type		PRAD
input02	EGFR MUT* (--)	EGFR inframe deletion (L747),inframe insertion (P753PS)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
input02	EGFR MUT* (--)	EGFR amplification	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259;PMID:22261807	only gene		HNC
input02	MET MUT* (--)	MET kinase domain mutation	Savolitinib(MET inhibitor)	Renal	Responsive	C	NO	PMID:28644771	only alteration type		R
input02	MET MUT* (--)	MET amplification	BCL2 inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:27397505	only gene		COREAD
input02	EGFR MUT* (--)	EGFR (V843I)	Gefitinib(EGFR inhibitor 1st gen)	Head an neck	No Responsive	C	NO	PMID:21274259	only alteration type		HNC
input02	MET MUT* (--)	MET amplification	MET inhibitors	Hepatic carcinoma	Responsive	C	NO	ENA 2015 (abstract A55)	only gene		HC
input02	MET MUT* (--)	MET amplification	MET inhibitors	Stomach	Responsive	D	NO	PMID:22729845;PMID:23327903	only gene		ST
input02	MET MUT* (--)	MET amplification	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094;AACR 2016 (abstr CT2006)	only gene		R
input02	BTK MUT* (F386)	BTK (C481)	Ibrutinib(BTK inhibitor)	Mantle cell lymphoma	Resistant	C	NO	PMID:25082755	only alteration type		MCL
input02	MET MUT* (--)	MET (H1112R)	MET inhibitors	Renal	Responsive	C	NO	PMID:23213094	only alteration type		R
input02	MET MUT* (--)	MET (M1268T)	MET inhibitors	Renal	Responsive	C	NO	PMID:23610116	only alteration type		R
input02	MET MUT* (--)	MET (H1112L)	MET inhibitors(Crizotinib,etc)	Any cancer type	Responsive	D	YES	AACR 2012 (abstr 1786)	only alteration type		CANCER
input02	MET MUT* (--)	MET amplification	Cabozantinib + Panitumumab(Pan-kinase inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	ENA 2015 (abstr A52)	only gene		COREAD
input02	MET MUT* (--)	MET fusion	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:27748748	only gene		G
input02	MET MUT* (--)	MET mutation in exon 16-19	Crizotinib(ALK inhibitor)	Renal	Responsive	C	NO	AACR 2016 (abstr CT2006)	only alteration type		R
input02	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Lung adenocarcinoma, Stomach	Responsive	C	NO	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	only gene		LUAD, ST
input02	MET MUT* (--)	MET amplification	Crizotinib(ALK inhibitor)	Glioma	Responsive	C	NO	PMID:22162573	only gene		G
input02	MET MUT* (--)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib(ALK inhibitor)	Any cancer type	Responsive	D	YES	PMID:17483355	only alteration type		CANCER
input02	MET MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	MET amplification + BRAF (V600E)	Crizotinib + Vemurafenib(ALK inhibitor + BRAF inhibitor)	Colorectal adenocarcinoma	Responsive	C	NO	PMID:27325282	only gene		COREAD
input02	KIT MUT* (P166L)	KIT (627-664,664-714,449-514)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458;PMID:18955451;PMID:16624552	only alteration type		GIST
input02	MET MUT* (--), ERBB2 MUT* (--), ERBB2 (G346D)	MET amplification + ERBB2 amplification	Crizotinib + Trastuzumab(ALK inhibitor + ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:26432108	only gene		ST
input02	MET MUT* (--), ERBB2 MUT* (--), ERBB2 (G346D)	MET amplification + ERBB2 amplification	Crizotinib + Trastuzumab(ALK inhibitor + ERBB2 mAb inhibitor)	Stomach	Responsive	C	NO	PMID:26432108	only gene		ST
input02	KIT MUT* (P166L)	KIT mutation in exon 17	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT mutation in exon 17 or 18	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:21690468;PMID:21642685	only alteration type		CM
input02	KIT MUT* (P166L)	KIT amplification	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:23775962	only gene		CM
input02	MPL MUT* (--)	MPL (W515F)	JAK inhibitors	Myelodisplasic proliferative syndrome	Responsive	D	NO	PMID:16834459	only alteration type		MDPS
input02	MSH3 (-380-381X)	MSH3 oncogenic mutation	DNA-PKc inhibitors	Any cancer type	Responsive	D	YES	PMID:24556366	complete		CANCER
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (F2108L)	MTOR kinase inhibitors	Any cancer type	Responsive	D	YES	PMID:25295501	only alteration type		CANCER
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (E2014K,E2419K,N1421D)	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:24625776	only alteration type		BLCA
input02	KIT MUT* (P166L)	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23582185;PMID:21689725;PMID:17259998	only alteration type		GIST
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (I1973F)	Everolimus(MTOR inhibitor)	Angiosarcoma, Renal	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		AS, R
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (K1771R)	Everolimus(MTOR inhibitor)	Stomach, Adrenal gland	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		ST, AG
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (N1421D)	Everolimus(MTOR inhibitor)	Stomach	Responsive	C	NO	PMID:26859683	only alteration type		ST
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (Q2223K)	Everolimus(MTOR inhibitor)	Renal	Responsive	C	NO	PMID:24622468	only alteration type		R
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (L1460P,S2215Y,R2505P)	Sirolimus(MTOR inhibitor)	Any cancer type	Responsive	D	YES	PMID:24631838	only alteration type		CANCER
input02	NF1 MUT* (--)	NF1 oncogenic mutation	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	AURK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	BRD4 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24373973	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	KIT inhibitor + MTOR inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24718867	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	MEK inhibitors	Glioma, Leukemia	Responsive	D	NO	PMID:22573716;PMID:19727076	only alteration type		G, LK
input02	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:23221341	only gene		MPN
input02	NF1 MUT* (--)	NF1 deletion	MEK inhibitors	Glioma, Leukemia	Responsive	D	NO	PMID:22573716;PMID:19727076	only gene		G, LK
input02	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	MTOR inhibitor + HSP90 inhibitors	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21907929	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	NO	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only alteration type		G, MPN, LK
input02	NF1 MUT* (--)	NF1 deletion	MTOR inhibitors	Glioma, Malignant peripheral nerve sheat tumor, Leukemia	Responsive	D	NO	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877	only gene		G, MPN, LK
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only alteration type		CM
input02	NF1 MUT* (--)	NF1 deletion	Pan-RAF inhibitor + MEK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:26351322	only gene		CM
input02	NF1 MUT* (--)	NF1 oncogenic mutation	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only alteration type		CM
input02	NF1 MUT* (--)	NF1 deletion	PD1 Ab inhibitors	Cutaneous melanoma	Responsive	C	NO	ASCO 2016 (abstr 105)	only gene		CM
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only alteration type		G
input02	NF1 MUT* (--)	NF1 deletion	Bevacizumab(VEGFR mAb inhibitor)	Glioma	Responsive	C	NO	PMID:24232489;PMID:2485933	only gene		G
input02	PDGFRA MUT* (--)	PDGFRA (T674I)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Hyper eosinophilic advanced snydrome	Resistant	C	NO	PMID:12660384	only alteration type		HES
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (K753E)	Lapatinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	D	NO	PMID:27697991	only alteration type		BRCA
input02	MET MUT* (--), ERBB2 MUT* (--), ERBB2 (G346D)	MET amplification + ERBB2 amplification	Lapatinib(ERBB2 inhibitor)	Stomach	Resistant	D	NO	PMID:22238368	only gene		ST
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only alteration type		HNC, SG
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus(MTOR inhibitor)	Neurofibroma	Responsive	B	NO	NCT01365468	only alteration type		NF
input02	NF1 MUT* (--)	NF1 (D1644A)	Everolimus(MTOR inhibitor)	Head an neck	Responsive	C	NO	ASCO 2015 (abstr 11010);PMID:26859683	only alteration type		HNC
input02	NF1 MUT* (--)	NF1 deletion	Everolimus(MTOR inhibitor)	Head an neck, Salivary glands	Responsive	C	NO	PMID:26859683;ASCO 2016 (abstr e17557)	only gene		HNC, SG
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Everolimus + Pazopanib(MTOR inhibitor + VEGFR inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24931142	only alteration type		HC
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only alteration type		PLEN
input02	NF1 MUT* (--)	NF1 deletion	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:23099009	only gene		PLEN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only alteration type		PLEN, MPN
input02	NF1 MUT* (--)	NF1 deletion	Nilotinib(BCR-ABL inhibitor 2nd gen)	Plexiform neurofibroma, Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:24173684	only gene		PLEN, MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only alteration type		PLEN
input02	NF1 MUT* (--)	NF1 deletion	PLX3397(Pan-TK inhibitor)	Plexiform neurofibroma	Responsive	D	NO	PMID:23099891	only gene		PLEN
input02	NF1 MUT* (--)	NF1 deletion	Selumetinib(MEK inhibitor)	Plexiform neurofibroma	Responsive	C	NO	ASCO 2014 (abstr 10018)	only gene		PLEN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only alteration type		PLEN
input02	NF1 MUT* (--)	NF1 deletion	Sirolimus(MTOR inhibitor)	Plexiform neurofibroma	Responsive	C	NO	PMID:25314964	only gene		PLEN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only alteration type		G
input02	NF1 MUT* (--)	NF1 deletion	Sirolimus + Erlotinib(MTOR inhibitor + EGFR inhibitor 1st gen)	Glioma	Responsive	C	NO	PMID:22434731	only gene		G
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	Sorafenib + Sirolimus(Pan-TK inhibitor + MTOR inhibitor)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:25810463	only gene		MPN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only alteration type		MPN
input02	NF1 MUT* (--)	NF1 deletion	Tamoxifen(Hormonal therapy)	Malignant peripheral nerve sheat tumor	Responsive	D	NO	PMID:21075781	only gene		MPN
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 (T798I)	Neratinib(ERBB2 inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:28274957	only alteration type		BRCA
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only alteration type		G
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only alteration type		CM
input02	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Glioma	Responsive	C	NO	PMID:26936308	only gene		G
input02	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24576830;PMID:2524381	only gene		CM
input02	EGFR MUT* (--)	EGFR (C797S)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	PMID:25939061	only alteration type		L
input02	EGFR MUT* (--)	EGFR (L718)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only alteration type		G
input02	NF1 MUT* (--)	NF1 deletion	Vinblastine(Chemotherapy)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 2019)	only gene		G
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only alteration type		G
input02	NF1 MUT* (--)	NF1 deletion	Vinblastine + Nilotinib(Chemotherapy + BCR-ABL inhibitor 2nd gen)	Glioma	Responsive	C	NO	ASCO 2016 (abstr 10555)	only gene		G
input02	EGFR MUT* (--)	EGFR (L792)	Osimertinib(EGFR inhibitor 3rd gen)	Lung	Resistant	C	NO	ASCO 2017 (abstr 2572)	only alteration type		L
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Osimertinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input02	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Osimertinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	B	NO	PMID:20619739;PMID:21163703;PMID:23325582	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR (G465R)	Panitumumab(EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:26059438	only alteration type		COREAD
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + CDK4 inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:19318552	only alteration type		ALL
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitor + MTOR inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:19246562	only alteration type		ALL
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 fusion	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:16688224;PMID:23033986	only gene		ALL
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	C	NO	ASCO 2006 (abstr 6585)	only alteration type		ALL
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Acute lymphoblastic leukemia	Responsive	D	NO	PMID:15472075;PMID:19778842;PMID:22510873;PMID:23001755	only alteration type		ALL
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:25564152	only alteration type		BRCA
input02	NOTCH1 (E2071K), NOTCH1 (-481-?)	NOTCH1 oncogenic mutation	Gamma secretase inhibitors	Mantle cell lymphoma	Responsive	D	NO	PMID:22210878	complete		MCL
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 splice donor variant (2245-2536),splice acceptor variant (2245-2536),stop gained (2245-2536),stop lost (2245-2536),frameshift variant (2245-2536)	NOTCH1 inhibitors	Adenoid cystic carcinoma	Responsive	C	NO	PMID:27870570	only alteration type		ADCC
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	Gamma secretase inhibitors(Ro4929097,Pf-03084014,Mk-0752,etc)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439; NCT01098344; NCT01981551	only alteration type		CANCER
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 activating mutation in Cterm-PEST domain	OMP-52M51(NOTCH1 inhibitor)	Any cancer type	Responsive	C	YES	NCT01703572;NCT01778439	only alteration type		CANCER
input02	NOTCH2 (GMVAELINCQA1958-1968X), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 fusion	Gamma secretase inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:22101766	only gene		BRCA
input02	NOTCH2 (GMVAELINCQA1958-1968X), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	Mk-0752(Gamma secretase inhibitor)	Breast adenocarcinoma, Acute myeloid leukemia, Acute lymphoblastic leukemia	Responsive	C	NO	PMID:25564152	only alteration type		BRCA, AML, ALL
input02	NOTCH2 (GMVAELINCQA1958-1968X), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--), NOTCH2 MUT* (--)	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	OMP-59R5(NOTCH2 inhibitor)	Solid tumors	Responsive	C	YES	NCT01859741;NCT01277146	only alteration type		SOLID
input02	NPM1 MUT* (--)	NPM1 oncogenic mutation	DOT1L inhibitors + MLL1 inhibitors	Acute myeloid leukemia	Responsive	D	NO	PMID:27535106	only alteration type		AML
input02	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (R489)	NRG1 fusion	Afatinib(ERBB2&EGFR inhibitor 2nd gen)	Lung adenocarcinoma	Responsive	C	NO	AACR 2016 (abstr 2631)	only gene		LUAD
input02	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (R489)	NRG1 fusion	Lapatinib(ERBB2 inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:24727320	only gene		LUAD
input02	NTRK3 MUT* (--)	NTRK3 fusion	IGF1R inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
input02	NTRK3 MUT* (--)	NTRK3 fusion	PI3K pathway inhibitors	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
input02	NTRK3 MUT* (--)	NTRK3 fusion	Midostaurin(Pan-TK inhibitor)	Breast adenocarcinoma	Responsive	D	NO	PMID:21148487;PMID:23131561	only gene		BRCA
input02	PAK1 MUT* (DA183-184A)	PAK1 amplification	PAK inhibitors	Cutaneous melanoma	Responsive	D	NO	PMID:23535073	only gene		CM
input02	PBRM1 MUT* (--)	PBRM1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
input02	PBRM1 MUT* (--)	PBRM1 deletion	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only gene		CANCER
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	HSP90 inhibitors	Gastrointestinal stromal	Responsive	D	NO	PMID:18794084	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Crenolanib(FLT3 inhibitor)	Gastrointestinal stromal	Responsive	C	NO	ASCO 2016 (abstr 11010)	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	Crenolanib(FLT3 inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
input02	PDGFRA MUT* (--)	PDGFRA (P577S,R841K,H845Y,G853D)	Imatinib(BCR-ABL inhibitor 1st gen&KIT inhibitor)	Cutaneous melanoma	Responsive	D	NO	PMID:24132921	only alteration type		CM
input02	EGFR MUT* (--)	EGFR (L798I)	Rociletinib(EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27283993	only alteration type		LUAD
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	AKT inhibitors	Breast adenocarcinoma	Responsive	C	NO	ASCO 2015 (abstr 2500)	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Rociletinib(3rd generation EGFR inhibitor)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitor(alone or in combination)s	Lung, Colorectal adenocarcinoma	Responsive	D	NO	PMID:23136191;PMID:23475782;PMID:22392911	only alteration type		L, COREAD
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Bladder, Head an neck, Lung	Responsive	C	NO	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)	only alteration type		BLCA, HNC, L
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Breast adenocarcinoma, Ovary, Cervix squamous cell, Endometrium	Responsive	C	NO	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)	only alteration type		BRCA, OV, CESC, ED
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Head an neck squamous	Responsive	C	NO	PMID:26787751;PMID:26763254	only alteration type		HNSC
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PI3K pathway inhibitors	Glioma, Thyroid carcinoma	Responsive	D	NO	PMID:19671762;PMID:21289267	only alteration type		G, THCA
input02	MET MUT* (--)	MET amplification	EGFR inhibitor 3rd gens(Rociletinib,etc)	Lung adenocarcinoma	Resistant	C	NO	PMID:27252416	only gene		LUAD
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Breast adenocarcinoma	Responsive	C	NO	PMID:28331003	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA oncogenic mutation	PIK3CA inhibitors	Stomach	Responsive	C	NO	ASCO 2015 (abstr 2501)	only alteration type		ST
input02	NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only alteration type		CM
input02	PIK3CA MUT* (--), ERBB2 MUT* (--), ERBB2 (G346D)	PIK3CA oncogenic mutation + ERBB2 amplification	Everolimus + Trastuzumab + Chemotherapy(MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:27091708	only gene		BRCA
input02	NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Selumetinib(MEK inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23444215	only gene		CM
input02	KIT MUT* (P166L)	KIT mutation in exon 11	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	B	NO	PMID:18955458	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT mutation in exon 17	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:23840364	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT amplification	Sunitinib(Pan-TK inhibitor)	Cutaneous melanoma	No Responsive	C	NO	PMID:22261812	only gene		CM
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Sunitinib(Pan-TK inhibitor)	Gastrointestinal stromal	Resistant	D	NO	PMID:22718859;PMID:16638875	only alteration type		GIST
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only alteration type		PLEN
input02	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD oncogenic mutation	IGF1R inhibitors	Sarcoma	Responsive	C	NO	PMID:23800680	only alteration type		S
input02	NF1 MUT* (--)	NF1 deletion	Tipifarnib(Farnesyltransferase inhibitor)	Plexiform neurofibroma	No Responsive	C	NO	PMID:24500418	only gene		PLEN
input02	NF1 MUT* (--)	NF1 oncogenic mutation	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only alteration type		OS
input02	NF1 MUT* (--)	NF1 deletion	Trametinib(MEK inhibitor)	Osteosarcoma	No Responsive	C	NO	PMID:26325560	only gene		OS
input02	RB1 MUT* (P23-)	RB1 oncogenic mutation	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only alteration type		RB
input02	RB1 MUT* (P23-)	RB1 deletion	HDAC inhibitors	Retinoblastoma	Responsive	D	NO	PMID:18483379	only gene		RB
input02	RB1 MUT* (P23-)	RB1 oncogenic mutation	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only alteration type		RB
input02	RB1 MUT* (P23-)	RB1 deletion	MDM2/MDMX inhibitors	Retinoblastoma	Responsive	D	NO	PMID:17080083;PMID:21515735	only gene		RB
input02	RB1 MUT* (P23-)	RB1 oncogenic mutation	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only alteration type		BLCA
input02	RB1 MUT* (P23-)	RB1 deletion	Cisplatin(Chemotherapy)	Bladder	Responsive	C	NO	PMID:26238431	only gene		BLCA
input02	ROS1 MUT* (F383)	ROS1 fusion	HSP90 inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:23533265	only gene		LUAD
input02	ROS1 MUT* (F383)	ROS1 fusion	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27370605	only gene		LUAD
input02	ROS1 MUT* (F383)	ROS1 (G2032R)	Cabozantinib(Pan-kinase inhibitor)	Lung adenocarcinoma	Responsive	D	NO	PMID:25351743	only alteration type		LUAD
input02	ROS1 MUT* (F383)	ROS1 fusion	Crizotinib(ALK inhibitor)	Inflammatory myofibroblastic	Responsive	C	NO	PMID:24875859	only gene		IM
input02	ROS1 MUT* (F383)	ROS1 fusion	Crizotinib(ALK inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:25264305	only gene		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Endometrium	No Responsive	C	NO	PMID:26099744;PMID:19840887	only gene		ED
input02	ROS1 MUT* (F383)	ROS1 (S1986Y,S1986F)	Lorlatinib(ALK&ROS1 inhibitor)	Lung adenocarcinoma	Responsive	C	NO	PMID:27401242	only alteration type		LUAD
input02	SETD2 MUT* (A2219V), SETD2 MUT* (--)	SETD2 oncogenic mutation	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only alteration type		CANCER
input02	SETD2 MUT* (A2219V), SETD2 MUT* (--)	SETD2 deletion	WEE1 inhibitors	Any cancer type	Responsive	D	YES	ENA 2014 (abstr 211)	only gene		CANCER
input02	MET MUT* (--), ERBB2 MUT* (--), ERBB2 (G346D)	MET amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma	Resistant	C	NO	PMID:22850551	only gene		BRCA
input02	SMARCA1 MUT* (--)	SMARCA1 oncogenic mutation	EZH2 inhibitors	Any cancer type	Responsive	D	YES	PMID:26552009	only alteration type		CANCER
input02	MET MUT* (--), ERBB2 MUT* (--), ERBB2 (G346D)	MET amplification + ERBB2 amplification	Trastuzumab(ERBB2 mAb inhibitor)	Breast adenocarcinoma, Stomach	Resistant	C	NO	PMID:22850551; PMID:26432108	only gene		BRCA, ST
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF inframe deletion (L485),inframe deletion (P490)	Vemurafenib(BRAF inhibitor)	Any cancer type	Resistant	D	YES	PMID:26732095	only alteration type		CANCER
input02	STK11 MUT* (--)	STK11 oncogenic mutation	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only alteration type		LUAD
input02	STK11 MUT* (--)	STK11 deletion	MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:19165201	only gene		LUAD
input02	STK11 MUT* (--)	STK11 oncogenic mutation	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only alteration type		CANCER
input02	STK11 MUT* (--)	STK11 deletion	MTOR inhibitors	Any cancer type	Responsive	D	YES	PMID:19541609	only gene		CANCER
input02	STK11 MUT* (--)	STK11 oncogenic mutation	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only alteration type		LUAD
input02	STK11 MUT* (--)	STK11 deletion	SRC inhibitor + PI3K/MEK inhibitors	Lung adenocarcinoma	Responsive	D	NO	PMID:20541700	only gene		LUAD
input02	STK11 MUT* (--)	STK11 (D194E)	Everolimus(MTOR inhibitor)	Pancreas	Responsive	C	NO	PMID:21189378	only alteration type		PA
input02	STK11 MUT* (--)	STK11 oncogenic mutation	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only alteration type		LUAD
input02	STK11 MUT* (--)	STK11 deletion	Phenformin(Anti-diabetic)	Lung adenocarcinoma	Responsive	D	NO	PMID:23352126	only gene		LUAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Vemurafenib(BRAF inhibitor)	Colorectal adenocarcinoma	No Responsive	C	NO	PMID:26287849	only alteration type		COREAD
input02	NF1 MUT* (--)	NF1 biallelic inactivation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	D	NO	PMID:23171796	only alteration type		CM
input02	SYK MUT* (--), SYK MUT* (--)	SYK amplification	SYK inhibitors	Mantle cell lymphoma, Chronic lymphocytic leukemia	Responsive	D	NO	PMID:16409295;PMID:19549911	only gene		MCL, CLL
input02	TERT (--)	TERT promoters core	Eribulin(Macrocyclic analog)	Glioblastoma multiforme	Responsive	D	NO	PMID:25375122;https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc;18/suppl_4/iv50-b	only alteration type		GBM
input02	TOP2A MUT* (--)	TOP2A amplification	Anthracyclines(Chemotherapy)	Breast adenocarcinoma	Responsive	B	NO	PMID:22864769	only gene		BRCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 (R248Q,R175H)	HSP90 inhibitors	Any cancer type	Responsive	D	YES	PMID:26009011	only alteration type		CANCER
input02	NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 oncogenic mutation + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only alteration type		CM
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	WEE1 inhibitors	Head an neck	Responsive	D	NO	PMID:25125259	complete		HNC
input02	NF1 MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	NF1 deletion + BRAF oncogenic mutation	Vemurafenib(BRAF inhibitor)	Cutaneous melanoma	Resistant	C	NO	PMID:23288408;PMID:231718	only gene		CM
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	NO	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	complete		BCL
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 deletion	AZD6738(ATR inhibitor)	B cell lymphoma	Responsive	C	NO	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	only gene		BCL
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Decitabine(Chemotherapy)	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	Responsive	C	NO	PMID:27959731	complete		AML, MDPS
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Doxorubicin(Anthracycline antitumor antibiotic)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Gemcitabine(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Mitomycin C(Chemotherapy)	Bladder	Responsive	D	NO	PMID:27397505	complete		BLCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	WEE1 inhibitors	Ovary	Responsive	C	NO	PMID:27998224	complete		OV
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 oncogenic mutation	Pramlintide(Amylin analogue)	Thymic	Responsive	D	NO	PMID:25409149	complete		THYM
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 deletion	Pramlintide(Amylin analogue)	Thymic	Responsive	D	NO	PMID:25409149	only gene		THYM
input02	MET MUT* (--), BRAF MUT* (--), BRAF MUT* (--)	MET amplification + BRAF (V600E)	Vemurafenib + Panitumumab(BRAF inhibitor + EGFR mAb inhibitor)	Colorectal adenocarcinoma	Resistant	C	NO	PMID:27325282	only gene		COREAD
input02	NTRK3 MUT* (--)	NTRK3 (G623R)	novel TRK inhibitors	Any cancer type	Responsive	C	YES	PMID:28578312	only alteration type		CANCER
input02	TSC2 MUT* (--)	TSC2 oncogenic mutation	MTOR inhibitors	Renal angiomyolipoma    	Responsive	C	NO	PMID:23312829;PMID:21525172;PMID:20048174	only alteration type		RA
input02	TSC2 MUT* (--)	TSC2 oncogenic mutation	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only alteration type		LAM
input02	TSC2 MUT* (--)	TSC2 deletion	SRC inhibitors	Lymphangioleiomyomatosis	Responsive	D	NO	PMID:24691995	only gene		LAM
input02	TSC2 MUT* (--)	TSC2 oncogenic mutation	Everolimus(MTOR inhibitor)	Bladder	Responsive	C	NO	PMID:22923433	only alteration type		BLCA
input02	TSC2 MUT* (--)	TSC2 (Q1178*)	Everolimus(MTOR inhibitor)	Thyroid carcinoma	Responsive	C	NO	PMID:25295501	only alteration type		THCA
input02	TSC2 MUT* (--)	TSC2 (E66K)	Tensirolimus(MTOR inhibitor)	Endometrium	Responsive	C	NO	PMID:27016228	only alteration type		ED
input02	VEGFA MUT* (--), VEGFA MUT* (--), VEGFA MUT* (--), VEGFA MUT* (--), VEGFA MUT* (--)	VEGFA amplification	Sorafenib(Pan-TK inhibitor)	Hepatic carcinoma	Responsive	C	NO	PMID:24687604	only gene		HC
input02	ZNRF3 (DS550-551D)	ZNRF3 oncogenic mutation	Porcupine inhibitors	Colorectal adenocarcinoma	Responsive	D	NO	PMID:26023187	complete		COREAD
input02	CXCR4 MUT* (--)	CXCR4	Ibrutinib(Kinase inhibitor )	Waldenstrm macroglobulinemia	Resistant	C	NO	PMID:31267520	only alteration type		WM
input02	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Cholangiocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CH
input02	EWSR1 MUT* (--), EWSR1 MUT* (--)	EWSR1-FLI1 fusion	T + K + 2 + 1 + 6	Ewing sarcoma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EWSR1	only gene		EWS
input02	EGFR MUT* (--)	EGFR (T790M)	Afatinib + Erlotinib + Gefitinib	Non-small cell lung	Resistant	A	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR (T790M,D761Y)	Gefitinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
input02	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Olaparib	Ovary	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/BRCA2|CIVIC=https://civicdb.org/genes/7/summary	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 deletion	Olaparib	Ovary	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		OV
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (L2209V,L1460P,L2427Q)	Temsirolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (Q2223K)	Everolimus	Renal clear cell	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		RCCC
input02	ALK MUT* (--)	ALK fusion	Crizotinib + Ceritinib	Sarcoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only gene		S
input02	ALK MUT* (--)	ALK (G1202R,I1171N)	Alectinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/ALK	only alteration type		NSCLC
input02	MET MUT* (--)	MET amplification	Crizotinib	Non-small cell lung	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/52/summary|oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
input02	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Crizotinib	Non-small cell lung	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Plx8394	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CANCER
input02	KIT MUT* (P166L)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,D816.,N655K,K642E,V560D,W557C,D60N,D816H)	Sunitinib + Sorafenib	Thymic	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		THYM
input02	KIT MUT* (P166L)	KIT (Y823D,T670I,V654A,D820G,C809G,D820A,N822K,D816H)	Imatinib	Gastrointestinal stromal	Resistant	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		GIST
input02	ERBB2 (G346D)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Neratinib	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	complete		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary	only gene		BRCA
input02	EGFR MUT* (--)	EGFR (R108K,T263P,A289V)	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		G
input02	EGFR MUT* (--)	EGFR (C797G,C797S)	Osimertinib	Non-small cell lung	Resistant	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR (E2419K,E2014K)	Everolimus	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	only alteration type		BLCA
input02	MTOR (S2215F)	MTOR (E2419K,C1483F,L2172M,K1452N,L2230V,L2427Q,L2431P,F1888I,E1799K,L2216P,W1456R,C1483W,A1519T,L1460P,A2210P,T2232I,R2505P,M2327I,C1483R,V2006I,A1428T,Y1463S,I2500M,A1459P,F1888L,S2231W,T1977R,V2006F,T1977K,A2226S,I2500F,L2427R,T1977I,S2215F,.,Q2223K,I1973F,L1433S,F1888V,S2215T,D2512H,E2014K,S2215Y,R2217W,L2209V,V2006L,L2220F,L2427P,S2215P,P2273S,E2288K,C1483Y)	Temsirolimus + Everolimus	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/MTOR	complete		CANCER
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Imatinib	Gastrointestinal stromal	Resistant	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
input02	NTRK3 MUT* (--)	NTRK3 fusion	Entrectinib	Any cancer type	Responsive	B	YES	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/3985/summary|oncokb=https://www.oncokb.org/gene/NTRK3	only gene		CANCER
input02	KDM6A (P972T), KDM6A MUT* (--)	KDM6A deletion	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	only gene		BLCA
input02	KDM6A (P972T)	KDM6A oncogenic mutation	Epz-6438 + Gsk343	Bladder	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/KDM6A	complete		BLCA
input02	MET MUT* (--)	MET (D1010H,Y1003N,D1010N,Y1003F,Y1003C,D1010Y)	Cabozantinib + Capmatinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600)	Panitumumab + Dabrafenib + Trametinib	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600E)	Encorafenib + Binimetinib + Cetuximab	Colorectal adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		OV
input02	KIT MUT* (P166L)	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,N655K,V560D,K642E,D816.,W557C,D60N,D816H)	Imatinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary	only alteration type		CM
input02	KIT MUT* (P166L)	KIT amplification	Imatinib	Cutaneous melanoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		CM
input02	KIT MUT* (P166L)	KIT (D816)	Blu-285	Mastocytosis	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only alteration type		MAS
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (S249C,S371C,R248C,K650.,G380R,Y373C,G370C)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		BLCA
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A (R87P,E69G,P48L,R112G,E88K,M53I,R87L,R80L,R99P,V118D,D108N,T77P,A36P,I49S,G101W,R80P,H83N,Q50P,A68T,A60R,G67S,G67R,G35R,L16P,D108H,R87W,N71I,L32P,N71K,P81L,.,R24P,H83Y,D74Y,G35V,G35A,D84Y,G23D,P73L,V126D,S56I,D84N,D74N,D84H,P114L,P114S,D84V,A60V,G93W,N71S,L97R,P81T,R79P,D84G)	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	complete		CANCER
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A deletion	Abemaciclib + Palbociclib + Ribociclib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/CDKN2A	only gene		CANCER
input02	PDGFRA MUT* (--)	PDGFRA (N659K,V561D,V561A,N659S,A633T,H845Y,T674I,S584L,D842V,N659R,D568N,P577S,D846Y,Q579R,D842Y,Y849S,N848K,H650Q,D842I,V469A,Y288C,Y555C,R748G,Y849C,.,R841K,G853D,V536E,V658A)	Imatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA amplification	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-BCR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-CDK5RAP2 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-ETV6 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-FIP1L1 fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-KDR fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-KIF5B fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	PDGFRA MUT* (--)	PDGFRA-STRN fusion	Imatinib	Gastrointestinal stromal	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/PDGFRA	only gene		GIST
input02	TSC2 MUT* (--)	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only alteration type		RCCC
input02	TSC2 MUT* (--)	TSC2 deletion	Everolimus	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/TSC2	only gene		RCCC
input02	ERBB2 (G346D)	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	complete		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 amplification	Ado + Trastuzumab + Neratinib	Non-small cell lung	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2	only gene		NSCLC
input02	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		BLCA
input02	FGFR2 MUT* (--)	FGFR2 (N549K,K526E,K641R,I547V,Y375C,D101Y,E219K,E565G,C382R,N549H,W290R,L617M,D530N,M535I,P253R,V564I,F276C,S252W,N549T,E731K,G271E,I642V,K641N,R203C,K659E,.,L617F,M537I,T341P,R678G,M391R,Y381D,V564F,K525E,N549S,R251Q,A648T,K659N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only alteration type		CANCER
input02	FGFR2 MUT* (--)	FGFR2 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-AHCYL1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-BICC1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-CCDC6 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-CIT fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-FAM76A fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-KIAA1967 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-MGEA5 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR2 MUT* (--)	FGFR2 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR2	only gene		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	Bladder	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		BLCA
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	Azd5363	Breast adenocarcinoma	Responsive	C	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/AKT1|CIVIC=https://civicdb.org/genes/2/summary	only alteration type		BRCA
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	Azd5363	Endometrial adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		EDA
input02	AKT1 MUT* (E117-)	AKT1 (E17K)	Azd5363	Ovary	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/AKT1	only alteration type		OV
input02	MET MUT* (--)	MET amplification	Erlotinib + Gefitinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Trametinib	Cutaneous melanoma	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF	only alteration type		CM
input02	NF1 MUT* (--)	NF1 deletion	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only gene		CANCER
input02	NF1 MUT* (--)	NF1 (K1436Q,R1391S,K1423E,R1276Q,T1324N,L1301R,R1204G,.,R1391G,V1398D,R1276P,S1463F,E1356G,R1204W,Y489C)	Cobimetinib + Trametinib	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NF1	only alteration type		CANCER
input02	PIK3CA MUT* (--)	PIK3CA (P539R,R38H,Q546K,G118D,G106V,Q546E,E579K,N345K,E453K,V344A,E545K,T1025S,E542Q,G1049R,M1043I,E110K,P449T,N1044K,K111E,C378R,H1047R,C420R,E78K,E545A,S629C,D350G,.,G451R,M1043V,E542V,Q546R,E365K,E81K,G106D,R88Q,P366R,R93Q,G914R,H1047Y,K111N,E545Q,E545G,R93W,R108H,G106R,E453Q,E542K,D1029Y,N345I,D549N,A1066V,Q546P,E542G,E453A)	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA amplification	Buparlisib + Alpelisib + Fulvestrant + Serabelisib + Copanlisib + Gdc + Taselisib + Fulvestrant + Alpelisib + Buparlisib + Fulvestrant + Taselisib	Breast adenocarcinoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/PIK3CA	only gene		BRCA
input02	EGFR MUT* (--)	EGFR (T790M,D761Y)	Osimertinib	Non-small cell lung	Responsive	A	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/19/summary|oncokb=https://www.oncokb.org/gene/EGFR	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK (C1156Y,F1174L,L1196M,G1269A)	Crizotinib	Non-small cell lung	Resistant	D	NO	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary	only alteration type		NSCLC
input02	KIT MUT* (P166L)	KIT amplification	Sunitinib + Sorafenib	Thymic	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/KIT	only gene		THYM
input02	MET MUT* (--)	MET (D1228N)	Crizotinib + Cabozantinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF fusion	Cobimetinib + Trametinib	Cutaneous melanoma	Responsive	C	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRAF	only gene		CM
input02	BRCA2 MUT* (--)	BRCA2 (R2659T,R2842C,E2663V,R2659K,L2653P,D2723A,S196N,R174C,V211I,R2336P,D2723H,D191G,N2829R,S206C,.,R2784W,R2602T,D3095E,G173C,D2723G,S142I,I2627F,R3052W,G2585R,R2336H,I2675V,L2647P,E3002K,G2748D)	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only alteration type		BRCA
input02	BRCA2 MUT* (--)	BRCA2 deletion	Talazoparib + Olaparib	Breast adenocarcinoma	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/BRCA2	only gene		BRCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 (M528I,D641N,R669G,Y373C,K650T,G370C,S249C,S371C,A391E,G380R,I538V,D641G,N540K,R248C,V555M,.,K650E,K650R,K650M,G375C,G382D,N540S,Y647C,K650Q,K650N)	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only alteration type		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 amplification	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3-BAIAP2L1 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3-TACC3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3-IGH fusion	Azd4547 + Erdafitinib + Nvp-Bgj398 + 1265229-25-1	Any cancer type	Responsive	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/FGFR3	only gene		CANCER
input02	PDGFRA MUT* (--)	PDGFRA (D842V)	Dasatinib	Gastrointestinal stromal	Responsive	B	NO	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/38/summary|oncokb=https://www.oncokb.org/gene/PDGFRA	only alteration type		GIST
input02	EGFR MUT* (--)	EGFR amplification	Lapatinib	Glioma	Responsive	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/EGFR	only gene		G
input02	NTRK3 MUT* (--)	NTRK3 (G623R)	Larotrectinib	Any cancer type	Resistant	D	YES	oncokb: oncokb=https://www.oncokb.org/gene/NTRK3	only alteration type		CANCER
input02	MET MUT* (--)	MET amplification	Cabozantinib	Renal clear cell	Responsive	B	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only gene		RCCC
input02	MET MUT* (--)	MET (Y1230H)	Crizotinib + Capmatinib	Non-small cell lung	Resistant	D	NO	oncokb: oncokb=https://www.oncokb.org/gene/MET	only alteration type		NSCLC
input02	ABCC3 MUT* (--)	ABCC3 Amplification	Monomethyl Auristatin E,Paclitaxel	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/951	only gene		BRCA
input02	AKT1 MUT* (E117-)	AKT1 E17K	Akt Inhibitor MK2206	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/231	only alteration type		BRCA
input02	AKT1 MUT* (E117-)	AKT1 E17K	Capivasertib	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/709	only alteration type		BRCA
input02	AKT1 MUT* (E117-)	AKT1 E17K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4029	only alteration type		CM
input02	AKT1 MUT* (E117-)	AKT1 E17K	Uprosertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/707	only alteration type		CM
input02	AKT1 MUT* (E117-)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/439	only alteration type		CM
input02	AKT1 MUT* (E117-)	AKT1 Q79K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4498	only alteration type		CM
input02	AKT1 MUT* (E117-)	AKT1 Q79K	Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/6260	only alteration type		CM
input02	AKT2 MUT* (--), AKT2 (E279K)	AKT2 Amplification	Everolimus,Vandetanib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1621	only gene		LUAD
input02	ALK MUT* (--)	ALK CAD::ALK	Entrectinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7481	only gene		COREAD
input02	ALK MUT* (--)	ALK CLTC::ALK	TAE684	Difuse large B Cell lymphoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1261	only gene		DLBCL
input02	ALK MUT* (--)	ALK CLTC::ALK	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1265	only gene		DLBCL
input02	ALK MUT* (--)	ALK EML4::ALK	Alectinib	Mesothelioma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9228	only gene		MESO
input02	ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/262	only gene		NSCLC
input02	ALK MUT* (--)	ALK EML4::ALK	WHI-P154	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1188	only gene		NSCLC
input02	ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Retaspimycin Hydrochloride	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1203	only gene		NSCLC
input02	ALK MUT* (--)	ALK EML4::ALK	Crizotinib,Alvespimycin	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1206	only gene		NSCLC
input02	ALK MUT* (--)	ALK EML4::ALK	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1207	only gene		NSCLC
input02	ALK MUT* (--)	ALK EML4::ALK	Lorlatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1332	only gene		NSCLC
input02	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/125	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	Alectinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/37	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/38	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/142	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1271	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	AZD3463	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1327	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1329	only alteration type		NB
input02	ALK MUT* (--)	ALK F1174L	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/33	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK F1245C	Crizotinib	Neuroblastoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1333	only alteration type		NB
input02	ALK MUT* (--)	ALK F1245C	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1330	only alteration type		NB
input02	ALK MUT* (--)	ALK F1245V	Entrectinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2987	only alteration type		NB
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1240	only gene		ALCL
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7361	only gene		ALCL
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Anaplastic large cell lymphoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11218	only gene		ALCL
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Difuse large B Cell lymphoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1264	only gene		DLBCL
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1691	only gene		LUAD
input02	ALK MUT* (--)	ALK Fusion	Pemetrexed	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/945	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1175	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1187	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1198	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1199	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1200	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1201	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Retaspimycin Hydrochloride	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1202	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1272	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1273	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1279	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1282	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1419	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1577	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4835	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib,Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4858	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7284	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Ceritinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7285	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Lorlatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7286	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Alectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/8657	only gene		NSCLC
input02	ALK MUT* (--)	ALK Fusion	Brigatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11121	only gene		NSCLC
input02	ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1283	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171	Crizotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1287	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171	Alectinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1367	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1284	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171	TAE684	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1285	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1344	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171	Ceritinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1368	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK I1171T	Ceritinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/9404	only alteration type		NB
input02	ALK MUT* (--)	ALK KANK4::ALK	Alectinib	Pancreas acinar	Responsive	C	NO	https://civicdb.org/links/evidence_items/10327	only gene		PAAC
input02	ALK MUT* (--)	ALK Mutation	Ceritinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1237	only alteration type		NSCLC
input02	ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1239	only gene		ALCL
input02	ALK MUT* (--)	ALK NPM::ALK	Crizotinib	Anaplastic large cell lymphoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1241	only gene		ALCL
input02	ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/48	only alteration type		NB
input02	ALK MUT* (--)	ALK R1275Q	TAE684	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/39	only alteration type		NB
input02	ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/143	only alteration type		NB
input02	ALK MUT* (--)	ALK R1275Q	Crizotinib	Neuroblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1270	only alteration type		NB
input02	ALK MUT* (--)	ALK R1275Q	Lorlatinib	Neuroblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1331	only alteration type		NB
input02	APC MUT* (--)	APC Mutation	G007-LK	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/446	only alteration type		COREAD
input02	AR MUT* (RQ85-86R), AR MUT* (--)	AR W742	Bicalutamide	Prostate adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/448	only alteration type		PRAD
input02	ASS1 MUT* (--), ASS1 MUT* (--)	ASS1 Loss	Carboplatin,Cisplatin,Taxol	Ovary	Resistant	D	NO	https://civicdb.org/links/evidence_items/5989	only gene		OV
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Non-V600	Trametinib	Solid tumors	Responsive	B	YES	https://civicdb.org/links/evidence_items/7855	only alteration type		SOLID
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF A598V	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7635	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF AGK::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/724	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF AGK::BRAF	Sorafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/723	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF CUX1::BRAF	Vemurafenib	Pancreas	Responsive	C	NO	https://civicdb.org/links/evidence_items/5977	only gene		PA
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF D594G	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1554	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2201	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF D594G	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4472	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF D594K	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6402	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF D594K	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6403	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF G466V	Irinotecan,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7552	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF G466V	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7553	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF G466V	Vemurafenib	Solid tumors	Responsive	D	YES	https://civicdb.org/links/evidence_items/7554	only alteration type		SOLID
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF G469	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7634	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF G596C	Dabrafenib,Trametinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1738	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF G596R	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4729	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1668	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF L505H	Vemurafenib	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1669	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF L597R	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/728	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1704	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Chemotherapy,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2187	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6303	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6304	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6305	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6306	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1404	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF PAPSS1::BRAF	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/725	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF PAPSS1::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/726	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF TRIM24::BRAF	Trametinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/727	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5905	only alteration type		CH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Refametinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1000	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/93	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1407	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1422	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1750	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Cobimetinib,Vemurafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/6044	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6180	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6937	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6966	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Binimetinib,Encorafenib	Cutaneous melanoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7287	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/88	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1576	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1415	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1598	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Cetuximab,Encorafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6046	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Encorafenib,Alpelisib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6047	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib,Irinotecan,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7355	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1574	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/94	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4488	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	Vemurafenib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4489	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7616	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600D	BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7629	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5902	only alteration type		CH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Irinotecan,Panitumumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5906	only alteration type		CH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Mirdametinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/86	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/90	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	MEK Inhibitor RO4987655	Cutaneous melanoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/994	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/95	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Pictilisib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/757	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Dactolisib,Selumetinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1005	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1398	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cobimetinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1421	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1749	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2135	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3750	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3755	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/3757	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6178	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6938	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6940	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/126	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/816	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2115	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2117	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2118	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2121	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,FOLFOX-4 Regimen	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3739	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3827	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Sorafenib,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/89	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	PLX4720,Pictilisib Bismesylate	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/96	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	PLX4720,Nutlin-3	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/97	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Bevacizumab,Capecitabine,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/98	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/99	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1405	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Dabrafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1406	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Gefitinib,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1408	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1413	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	GDC-0879,Dactolisib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1428	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1589	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Irinotecan,Vemurafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1902	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5960	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Dabrafenib,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6123	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Panitumumab,Trametinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6124	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Cetuximab,Encorafenib,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7260	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab,Binimetinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7612	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Cetuximab,Irinotecan	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8506	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib,Erlotinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8507	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Encorafenib,Cetuximab	Colorectal adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/9851	only alteration type		COREAD
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Hairy-Cell leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/1579	only alteration type		HCL
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5903	only alteration type		IHCH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Trametinib,Dabrafenib	Intrahepatic cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5904	only alteration type		IHCH
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1698	only alteration type		MM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Multiple myeloma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1699	only alteration type		MM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Dabrafenib,Trametinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/3017	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5958	only alteration type		NSCLC
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600E	Vemurafenib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/5959	only alteration type		OV
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1399	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1400	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2505	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Trametinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2506	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Vemurafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4180	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6179	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF V600K	Trametinib,Dabrafenib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6965	only alteration type		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF ZKSCAN1::BRAF	Trametinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1663	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Amplification	Trametinib,Dabrafenib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/7677	only gene		CM
input02	BRAF MUT* (--), BRAF MUT* (--)	BRAF Amplification	Panitumumab,Dabrafenib	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2929	only gene		COREAD
input02	BRCA2 MUT* (--)	BRCA2 M1I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2880	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 M1R	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2879	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	B	NO	https://civicdb.org/links/evidence_items/2868	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 Mutation	Rucaparib	Ovary	Responsive	A	NO	https://civicdb.org/links/evidence_items/11137	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 R2336P	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2884	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 V159M	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2881	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 V211I	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2883	only alteration type		OV
input02	BRCA2 MUT* (--)	BRCA2 V211L	Rucaparib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/2882	only alteration type		OV
input02	CDK12 MUT* (--)	CDK12 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11204	only alteration type		PRAD
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A Mutation	Palbociclib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7300	complete		CH
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A Mutation	Palbociclib	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/7299	complete		PA
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A Loss	Linsitinib,Palbociclib	Ewing sarcoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1879	only gene		EWS
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A Loss	Palbociclib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/7444	only gene		NSCLC
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A Loss	Palbociclib	Ovary	Responsive	D	NO	https://civicdb.org/links/evidence_items/1377	only gene		OV
input02	CDKN2A (D74A), CDKN2A (R58*)	CDKN2A Loss	Palbociclib	Renal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1373	only gene		R
input02	CEBPA MUT* (PP188-189P)	CEBPA Mutation	Tretinoin	Acute myeloid leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/122	only alteration type		AML
input02	CHEK1 MUT* (--)	CHEK1 Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11210	only alteration type		PRAD
input02	DNMT3A MUT* (--)	DNMT3A Mutation	Decitabine	Acute myeloid leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/1587	only alteration type		AML
input02	DNMT3A MUT* (--)	DNMT3A R882	Daunorubicin	Acute myeloid leukemia	Resistant	B	NO	https://civicdb.org/links/evidence_items/11	only alteration type		AML
input02	DNMT3A MUT* (--)	DNMT3A R882	Idarubicin	Acute myeloid leukemia	Responsive	B	NO	https://civicdb.org/links/evidence_items/18	only alteration type		AML
input02	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4497	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR A763_Y764insFQEA	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9225	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR A767_V769dupASV	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4665	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR A767_V769dupASV	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9220	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR A864T	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4495	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR C797S	Osimertinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1396	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR C797S	Osimertinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/964	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR D761Y	Erlotinib,Gefitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1763	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR D770_N771insG	Osimertinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/9223	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR D770_N771insGL	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4494	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR D770_N771insGT	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4643	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR D770_N771insNPG	Gefitinib,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/5947	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR D770delinsGY	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4801	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR E746G	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1787	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2625	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR E746_A750del	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4198	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5909	only gene		LUAD
input02	EGFR MUT* (--)	EGFR EGFR::RAD51	Icotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7314	only gene		LUAD
input02	EGFR MUT* (--)	EGFR EGFR::RAD51	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11015	only gene		LUAD
input02	EGFR MUT* (--)	EGFR EGFR::RAD51	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11021	only gene		LUAD
input02	EGFR MUT* (--)	EGFR G465R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1058	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR G465R	Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1057	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR G719	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1780	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR G719	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4189	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G719A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2508	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G719A	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6181	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G719D	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4210	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G719S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/787	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR G719S	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/274	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G719S	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1736	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G719S	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4190	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR G724S	Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/786	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR H773_V774insNPH	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4493	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR K467T	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1083	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR K467T	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1082	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR K757R	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1786	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR K806E	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4239	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR KIF5B::EGFR	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11026	only gene		LUAD
input02	EGFR MUT* (--)	EGFR L747P	Gefitinib,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4220	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4266	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L747_P753delinsS	Erlotinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6005	only alteration type		PAAD
input02	EGFR MUT* (--)	EGFR L747_S752delinsQ	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4667	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L838P	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4252	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/879	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/883	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Afatinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/982	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2624	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/2634	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/4290	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4291	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Cetuximab	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/4292	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib	Lung adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6183	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR L858R	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4288	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/229	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/275	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/276	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/885	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/968	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1665	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2621	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Lapatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2626	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2627	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2628	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2629	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2631	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2632	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2994	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Afatinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/2997	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4284	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4286	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4287	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4294	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4860	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L858R	Erlotinib	Small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4293	only alteration type		SCLC
input02	EGFR MUT* (--)	EGFR L861	Gefitinib,Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/4298	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L861Q	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/3802	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR L861R	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4669	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR M766_A767insAI	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4799	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1728	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1937	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2053	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2148	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Afatinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2153	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/2559	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3016	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/3794	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4201	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Mutation	Erlotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/7024	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR N826S	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4496	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR N826Y	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4244	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR N842S	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4256	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR P772_H773insYNP	Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/4802	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR R451C	Futuximab/Modotuximab Mixture,Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1081	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR R705K	Erlotinib,Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/6182	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR R776C	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4468	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/717	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR S492R	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1080	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR S492R	Panitumumab	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1078	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR S492R	Panitumumab,Futuximab/Modotuximab Mixture	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1079	only alteration type		COREAD
input02	EGFR MUT* (--)	EGFR S720	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1782	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4273	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR S768I	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1394	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR S768I	Gefitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1395	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR S768I	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/2906	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1391	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1397	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/2157	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR T790M	Erlotinib	Non-small cell lung	Resistant	A	NO	https://civicdb.org/links/evidence_items/238	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/239	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/240	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1667	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/1863	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Gefitinib,Erlotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/2158	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2159	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Lapatinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/2160	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Pemetrexed,Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/277	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/646	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Rociletinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/762	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/963	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/965	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/966	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Rociletinib,Osimertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/967	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1592	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/1867	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Dacomitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2161	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Neratinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2162	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2163	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2164	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Canertinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2165	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR T790M	Osimertinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6006	only alteration type		PAAD
input02	EGFR MUT* (--)	EGFR T847I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4260	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR V742A	Erlotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/4197	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR V769_D770insASV	Erlotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1799	only alteration type		LUAD
input02	EGFR MUT* (--)	EGFR V774A	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4226	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR V774M	Erlotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4231	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR V834I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4248	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR V851I	Gefitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4264	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Y764_V765insHH	Erlotinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/4800	only alteration type		NSCLC
input02	EGFR MUT* (--)	EGFR Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/854	only gene		COREAD
input02	EGFR MUT* (--)	EGFR Amplification	Cetuximab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/911	only gene		COREAD
input02	EGFR MUT* (--)	EGFR Amplification	Platinum Compound,Cetuximab,Fluorouracil	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/691	only gene		HNSC
input02	EGFR MUT* (--)	EGFR Amplification	Rociletinib,Osimertinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/3015	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR Amplification	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/948	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/977	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5924	only gene		NSCLC
input02	EGFR MUT* (--)	EGFR Amplification	Erlotinib,Gefitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5925	only gene		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 D769H	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/279	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 D769Y	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/280	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 G309A	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/282	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 G776L	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1889	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 G778_P780DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1890	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 G778_P780DUP	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1892	only alteration type		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 L755S	Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/241	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 L755S	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/283	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 L755S	Fluorouracil,Trastuzumab,Leucovorin	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4955	only alteration type		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 L755W	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/284	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 L755_T759del	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/281	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 M774DELINSWLV	Dacomitinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1894	only alteration type		NSCLC
input02	ERBB2 (G346D)	ERBB2 Mutation	Platinum Compound	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/1694	complete		BLCA
input02	ERBB2 (G346D)	ERBB2 Mutation	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5338	complete		BRCA
input02	ERBB2 (G346D)	ERBB2 Mutation	Trastuzumab,Pertuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/5980	complete		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 P780INS	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/285	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 P780INS	Dacomitinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1048	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 R678Q	Lapatinib,Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/286	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 R896C	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/287	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 T798I	Osimertinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/6174	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 V777L	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/288	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 V842I	Neratinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/289	only alteration type		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1045	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Y772_A775DUP	Trastuzumab Emtansine	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1125	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Y772_A775DUP	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1888	only alteration type		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Y772_A775DUP	Sirolimus,Afatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/960	only alteration type		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Y772_A775DUP	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1893	only alteration type		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/5982	only gene		BLCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/528	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/529	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	AKTi-1/2	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/760	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Neratinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/761	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib,Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/887	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/961	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1006	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1007	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Lapatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1008	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1009	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1011	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1012	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1013	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pertuzumab,Docetaxel,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1077	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Neratinib,Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1113	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/1122	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Lapatinib,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1132	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Capecitabine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1133	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1159	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1160	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1380	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	A66	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1381	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Tgx 221	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1382	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1432	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Docetaxel,Pertuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1437	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Lapatinib,Trastuzumab	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1439	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pilaralisib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1448	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Palbociclib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1561	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	MTOR Kinase Inhibitor PP242	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1613	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab Emtansine	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1764	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2071	only gene		BRCA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Pertuzumab	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7638	only gene		CH
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Capecitabine,Cetuximab,Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/895	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1686	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1687	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1688	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1993	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Lapatinib	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1689	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5981	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7302	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7807	only gene		COREAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/1098	only gene		ED
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1393	only gene		LUAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1041	only gene		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1042	only gene		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab Emtansine	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1050	only gene		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Dacomitinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1891	only gene		NSCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Pancreas	Responsive	B	NO	https://civicdb.org/links/evidence_items/5985	only gene		PA
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Afatinib	Pancreas adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/962	only gene		PAAD
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab,Irinotecan	Small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1044	only gene		SCLC
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Pertuzumab,Trastuzumab	Salivary glands	Responsive	B	NO	https://civicdb.org/links/evidence_items/5984	only gene		SG
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1022	only gene		ST
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Lapatinib	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/1023	only gene		ST
input02	ERBB2 MUT* (--), ERBB2 (G346D)	ERBB2 Amplification	Trastuzumab	Stomach	Responsive	A	NO	https://civicdb.org/links/evidence_items/1499	only gene		ST
input02	ERBB4 MUT* (--), ERBB4 MUT* (--), ERBB4 MUT* (--)	ERBB4 Mutation	Lapatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/770	only alteration type		CM
input02	FBXW7 MUT* (--), FBXW7 MUT* (--)	FBXW7 Mutation	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/718	only alteration type		COREAD
input02	FGFR2 MUT* (--)	FGFR2 FGFR2::AHCYL1	Infigratinib,PD173074	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1853	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 FGFR2::BICC1	PD173074,Infigratinib	Cholangiocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1851	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 FGFR2::BICC1	Erdafitinib	Endometrium	Responsive	C	NO	https://civicdb.org/links/evidence_items/1920	only gene		ED
input02	FGFR2 MUT* (--)	FGFR2 FGFR2::MGEA5	Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/295	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 FGFR2::TACC3	Pazopanib,Ponatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/296	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1913	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 Fusion	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5908	only gene		CH
input02	FGFR2 MUT* (--)	FGFR2 Fusion	Derazantinib	Intrahepatic cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/7329	only gene		IHCH
input02	FGFR2 MUT* (--)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1912	only alteration type		CH
input02	FGFR2 MUT* (--)	FGFR2 Mutation	Infigratinib	Cholangiocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5912	only alteration type		CH
input02	FGFR2 MUT* (--)	FGFR2 Mutation	Ponatinib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1236	only alteration type		ED
input02	FGFR2 MUT* (--)	FGFR2 N550K	PD173074	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1322	only alteration type		ED
input02	FGFR2 MUT* (--)	FGFR2 P253R	Pazopanib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/7833	only alteration type		HNSC
input02	FGFR2 MUT* (--)	FGFR2 Amplification	Dovitinib	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1605	only gene		BRCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 FGFR3::BAIAP2L1	PD173074	Bladder	Responsive	D	NO	https://civicdb.org/links/evidence_items/144	only gene		BLCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 Mutation	Infigratinib	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/1910	only alteration type		BLCA
input02	FGFR3 MUT* (--), FGFR3 MUT* (--)	FGFR3 Mutation	Cisplatin,Gemcitabine	Bladder	Responsive	B	NO	https://civicdb.org/links/evidence_items/7566	only alteration type		BLCA
input02	GNAQ (A18V)	GNAQ Mutation	JQ1	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1210	complete		UVM
input02	GNAQ (A18V)	GNAQ Mutation	Trametinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1229	complete		UVM
input02	GNAQ (A18V)	GNAQ Mutation	Mirdametinib,Sotrastaurin Acetate	Uveal melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1953	complete		UVM
input02	GNAQ (A18V)	GNAQ Mutation	Cabozantinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/5068	complete		UVM
input02	GNAQ (A18V)	GNAQ Q209	Selumetinib	Uveal melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1213	only alteration type		UVM
input02	GNAQ (A18V)	GNAQ Q209	Refametinib	Uveal melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1233	only alteration type		UVM
input02	GNAS MUT* (--), GNAS MUT* (--), GNAS MUT* (--)	GNAS R201C	Cetuximab,Vemurafenib,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1906	only alteration type		COREAD
input02	JAK1 MUT* (--)	JAK1 S703I	Ruxolitinib	Hepatic carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1900	only alteration type		HC
input02	KIT MUT* (P166L)	KIT A502_Y503insAY	Regorafenib,Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4630	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT A502_Y503insAY	Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7392	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT A829P	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7413	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT A829P	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7415	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT C809G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2920	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D579del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4142	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D816E	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4631	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D816E	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7401	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D816H	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2923	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D816V	Midostaurin	Systemic mastocytosis	Responsive	B	NO	https://civicdb.org/links/evidence_items/1725	only alteration type		SM
input02	KIT MUT* (P166L)	KIT D820A	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2921	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D820G	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2922	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT D820Y	Imatinib	Cutaneous melanoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2886	only alteration type		CM
input02	KIT MUT* (P166L)	KIT D820Y	Sunitinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2888	only alteration type		CM
input02	KIT MUT* (P166L)	KIT D820Y	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4589	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT K550_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4062	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT K550_W557del	Ponatinib,Regorafenib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4583	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT K558delinsNP	Imatinib,Regorafenib,Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4594	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT K642E	Dasatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4147	only alteration type		CM
input02	KIT MUT* (P166L)	KIT K642E	Sunitinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7397	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT L576P	Nilotinib,Sorafenib,Imatinib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/34	only alteration type		CM
input02	KIT MUT* (P166L)	KIT L576P	Dasatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/42	only alteration type		CM
input02	KIT MUT* (P166L)	KIT L576P	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4136	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT L576P	Nilotinib,Dasatinib,Imatinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/303	only alteration type		NSCLC
input02	KIT MUT* (P166L)	KIT Mutation	Imatinib	Cutaneous melanoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1222	only alteration type		CM
input02	KIT MUT* (P166L)	KIT Mutation	Pictilisib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/919	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT N822K	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7370	only alteration type		AML
input02	KIT MUT* (P166L)	KIT N822K	Ponatinib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7379	only alteration type		AML
input02	KIT MUT* (P166L)	KIT N822K	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2918	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT N822K	Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4167	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT N822K	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4169	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT N822K	Sunitinib,Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7414	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT N822K	Regorafenib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/4595	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT S628N	Imatinib	Cutaneous melanoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/7463	only alteration type		CM
input02	KIT MUT* (P166L)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2924	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT T670I	Regorafenib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/4510	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT T670I	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7416	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT T670I	Sunitinib,Ponatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/7417	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V559D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/3028	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V559D	Imatinib,Regorafenib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4459	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V560D	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4122	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V560D	Regorafenib,Ponatinib,Imatinib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4127	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V560G	Ponatinib,Regorafenib,Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/7395	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V654A	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/249	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT V654A	Sunitinib	Gastrointestinal stromal	Responsive	B	NO	https://civicdb.org/links/evidence_items/304	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT W557_K558del	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4082	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT W557_K558del	Imatinib,Ponatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4084	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT W557_K558del	Regorafenib,Sunitinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/4087	only alteration type		GIST
input02	KIT MUT* (P166L)	KIT Y823D	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2919	only alteration type		GIST
input02	KMT2C (G4457S), KMT2C (SL3788-3789X), KMT2C MUT* (--), KMT2C MUT* (--), KMT2C MUT* (--)	KMT2C Loss	Aromatase Inhibitor	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6484	only gene		BRCA
input02	KRAS wildtype	KRAS Wildtype	Regorafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8840	complete		COREAD
input02	MAPK1 MUT* (--)	MAPK1 E322K	Erlotinib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/791	only alteration type		HNSC
input02	MAPK1 MUT* (--)	MAPK1 Amplification	WZ4002	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/792	only gene		NSCLC
input02	MET MUT* (--)	MET D1228N	Crizotinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1652	only alteration type		NSCLC
input02	MET MUT* (--)	MET D1228V	Savolitinib	Non-small cell lung	Resistant	C	NO	https://civicdb.org/links/evidence_items/1865	only alteration type		NSCLC
input02	MET MUT* (--)	MET D1228V	Cabozantinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1864	only alteration type		NSCLC
input02	MET MUT* (--)	MET MET::ATXN7L1	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/7793	only gene		NSCLC
input02	MET MUT* (--)	MET Amplification	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1971	only gene		COREAD
input02	MET MUT* (--)	MET Amplification	Vemurafenib,Crizotinib	Colorectal adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1588	only gene		COREAD
input02	MET MUT* (--)	MET Amplification	Crizotinib,Cetuximab	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1979	only gene		COREAD
input02	MET MUT* (--)	MET Amplification	Crizotinib	Glioblastoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1565	only gene		GB
input02	MET MUT* (--)	MET Amplification	Erlotinib,Gefitinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1392	only gene		LUAD
input02	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/836	only gene		LUAD
input02	MET MUT* (--)	MET Amplification	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1692	only gene		LUAD
input02	MET MUT* (--)	MET Amplification	Crizotinib	Lung squamous cell	Responsive	C	NO	https://civicdb.org/links/evidence_items/890	only gene		LUSC
input02	MET MUT* (--)	MET Amplification	Gefitinib	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/733	only gene		NSCLC
input02	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/735	only gene		NSCLC
input02	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1566	only gene		NSCLC
input02	MET MUT* (--)	MET Amplification	Crizotinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/1713	only gene		NSCLC
input02	MET MUT* (--)	MET Amplification	Onartuzumab	Stomach	Responsive	C	NO	https://civicdb.org/links/evidence_items/689	only gene		ST
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR A2034V	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1547	only alteration type		BRCA
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR A2034V	RapaLink-1,MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1548	only alteration type		BRCA
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR E1799K	Sirolimus	Renal clear cell	Responsive	D	NO	https://civicdb.org/links/evidence_items/1321	only alteration type		RCCC
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR F2108L	Sirolimus	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1543	only alteration type		BRCA
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR F2108L	Everolimus	Thyroid carcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1110	only alteration type		THCA
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR H1968Y	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/713	only alteration type		CM
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR M2327I	MTOR Kinase Inhibitor AZD8055	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1544	only alteration type		BRCA
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR M2327I	Sirolimus,RapaLink-1	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1545	only alteration type		BRCA
input02	MTOR (S2215F)	MTOR Mutation	Everolimus,Pazopanib	Bladder	Responsive	C	NO	https://civicdb.org/links/evidence_items/705	complete		BLCA
input02	MTOR (S2215F), MTOR MUT* (--)	MTOR P2213S	PI3K/BET Inhibitor LY294002,Capivasertib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/722	only alteration type		CM
input02	NOTCH1 MUT* (PQ2415-2416Q), NOTCH1 (E2071K), NOTCH1 MUT* (--), NOTCH1 (-481-?)	NOTCH1 Amplification	NOTCH1 Antibody (PF-06293622)	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/811	only gene		COREAD
input02	NPM1 MUT* (--)	NPM1 W288FS	NSC348884	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/152	only alteration type		AML
input02	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (R489)	NRG1 ATP1B1::NRG1	Afatinib	Cholangiocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5858	only gene		CH
input02	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (R489)	NRG1 Fusion	Afatinib	Pancreas adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/6273	only gene		PAAD
input02	NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (--), NRG1 MUT* (R489)	NRG1 SDC4::NRG1	Afatinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/5859	only gene		LUAD
input02	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/11099	only gene		LUAD
input02	NTRK3 MUT* (--)	NTRK3 EML4::NTRK3	Entrectinib	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/10636	only gene		NSCLC
input02	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Entrectinib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7994	only gene		AML
input02	NTRK3 MUT* (--)	NTRK3 ETV6::NTRK3	Larotrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/7496	only gene		SOLID
input02	NTRK3 MUT* (--)	NTRK3 F617L	Larotrectinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/9592	only alteration type		GIST
input02	NTRK3 MUT* (--)	NTRK3 Fusion	Larotrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/6568	only gene		SOLID
input02	NTRK3 MUT* (--)	NTRK3 Fusion	Entrectinib	Solid tumors	Responsive	A	YES	https://civicdb.org/links/evidence_items/11125	only gene		SOLID
input02	PDGFRA MUT* (--)	PDGFRA D842I	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/43	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/15	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/16	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	D	NO	https://civicdb.org/links/evidence_items/651	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	B	NO	https://civicdb.org/links/evidence_items/738	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Imatinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/2478	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Sunitinib	Gastrointestinal stromal	Resistant	C	NO	https://civicdb.org/links/evidence_items/4597	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842V	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/44	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842Y	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/45	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA D842_I843delinsVM	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/47	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA FIP1L1::PDGFRA	Sunitinib,Sorafenib	Acute myeloid leukemia	Responsive	D	NO	https://civicdb.org/links/evidence_items/7378	only gene		AML
input02	PDGFRA MUT* (--)	PDGFRA G853D	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1977	only alteration type		CM
input02	PDGFRA MUT* (--)	PDGFRA H845Y	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1976	only alteration type		CM
input02	PDGFRA MUT* (--)	PDGFRA I843DEL	Crenolanib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/46	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA I843DEL	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/1309	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA Mutation	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2487	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA P577S	Crenolanib,Imatinib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1974	only alteration type		CM
input02	PDGFRA MUT* (--)	PDGFRA R841K	Imatinib,Crenolanib	Cutaneous melanoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1975	only alteration type		CM
input02	PDGFRA MUT* (--)	PDGFRA V561A	Imatinib	Gastrointestinal stromal	Responsive	D	NO	https://civicdb.org/links/evidence_items/652	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA V561D	Imatinib	Gastrointestinal stromal	Responsive	C	NO	https://civicdb.org/links/evidence_items/2474	only alteration type		GIST
input02	PDGFRA MUT* (--)	PDGFRA Amplification	Sunitinib	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1771	only gene		NSCLC
input02	PDGFRB MUT* (--), PDGFRB MUT* (--)	PDGFRB Fusion	Imatinib	Malignant peripheral nerve sheat tumor	Responsive	A	NO	https://civicdb.org/links/evidence_items/1498	only gene		MPN
input02	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2346	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA C420R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8549	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA C420R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2078	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA C420R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1999	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA D350G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4784	only alteration type		CM
input02	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8007	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/310	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	Sirolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/311	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2022	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2026	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2058	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7315	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8013	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8016	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E542K	Regorafenib	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/83	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA E542K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4424	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA E542K	Apitolisib	Head an neck squamous	Responsive	C	NO	https://civicdb.org/links/evidence_items/1549	only alteration type		HNSC
input02	PIK3CA MUT* (--)	PIK3CA E542K	Perifosine,Temsirolimus	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1626	only alteration type		THCA
input02	PIK3CA MUT* (--)	PIK3CA E545	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7468	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545G	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3724	only alteration type		CM
input02	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1453	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2036	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6211	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6213	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	PI-103	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8008	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8547	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Akt Inhibitor MK2206,Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/710	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2034	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2062	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8017	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8018	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA E545K	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3722	only alteration type		CM
input02	PIK3CA MUT* (--)	PIK3CA E545K	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/387	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2037	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA E545K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2217	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib	Lung adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1171	only alteration type		LUAD
input02	PIK3CA MUT* (--)	PIK3CA E545K	Gefitinib,Erlotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/1670	only alteration type		LUAD
input02	PIK3CA MUT* (--)	PIK3CA E545K	PI103	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/2040	only alteration type		NSCLC
input02	PIK3CA MUT* (--)	PIK3CA E545Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2213	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA E81K	Oxaliplatin,Fluorouracil,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4464	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA F930S	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10032	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA G1049R	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3847	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047L	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2089	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047L	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8009	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047L	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8019	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4432	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2103	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6204	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6206	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8548	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	PI3K-alpha Inhibitor MEN1611	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/314	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Capivasertib,Trastuzumab	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1505	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Lapatinib,Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1506	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Everolimus,Fulvestrant	Breast adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1623	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2096	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2102	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/258	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Cetuximab,Panitumumab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/388	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Vemurafenib	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/3733	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Irinotecan,Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3841	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Akt Inhibitor MK2206,Vemurafenib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8364	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1465	only alteration type		HNSC
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Dactolisib	Lung adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1447	only alteration type		LUAD
input02	PIK3CA MUT* (--)	PIK3CA H1047R	Temsirolimus,Perifosine	Thyroid carcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1625	only alteration type		THCA
input02	PIK3CA MUT* (--)	PIK3CA H1047X	Alpelisib,Fulvestrant	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7318	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2867	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA I391M	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8663	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/2866	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K111N	Dactolisib,Trastuzumab,Lapatinib	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8183	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K111N	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8662	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K111N	Pictilisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/2085	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K111N	PI-103	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8011	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K111N	PI3Ka/Di	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8020	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA K944N	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10031	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA K966E	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10034	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/1384	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2087	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/2098	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Trastuzumab Emtansine	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8536	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Capecitabine,Lapatinib	Breast adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/8705	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Everolimus	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/1296	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Capivasertib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1504	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1600	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Palbociclib,Phosphatidylinositide 3-Kinase Inhibitor	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1607	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	MTOR Kinase Inhibitor PP242,Everolimus	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/1610	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Fulvestrant,Alpelisib	Breast adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/7313	only alteration type		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Anti-EGFR Monoclonal Antibody	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/915	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1705	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab,Chemotherapy	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/3732	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Oxaliplatin	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6298	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Irinotecan	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6299	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Bevacizumab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6300	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6301	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Panitumumab,Cetuximab	Colorectal adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6362	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Cabozantinib	Colorectal adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/771	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin	Colorectal adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/6375	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Ridaforolimus,Temsirolimus	Endometrium	Responsive	B	NO	https://civicdb.org/links/evidence_items/892	only alteration type		ED
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Pictilisib	Endometrium	Responsive	D	NO	https://civicdb.org/links/evidence_items/1616	only alteration type		ED
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Radiation Therapy,Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1490	only alteration type		HNSC
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Aspirin,Sulindac,Celecoxib	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7185	only alteration type		HNSC
input02	PIK3CA MUT* (--)	PIK3CA Mutation	Erlotinib,Gefitinib	Non-small cell lung	Resistant	B	NO	https://civicdb.org/links/evidence_items/2355	only alteration type		NSCLC
input02	PIK3CA MUT* (--)	PIK3CA N345K	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4047	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Q546K	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2198	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA R88Q	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/3832	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA R93W	Cetuximab,Fluorouracil,Oxaliplatin	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4467	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA S158L	Cetuximab,Irinotecan	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/4463	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA V955G	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/10033	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA V955I	Cetuximab	Colorectal adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/8063	only alteration type		COREAD
input02	PIK3CA MUT* (--)	PIK3CA Amplification	Trastuzumab	Breast adenocarcinoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/8267	only gene		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Amplification	Lapatinib,Dactolisib	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/8271	only gene		BRCA
input02	PIK3CA MUT* (--)	PIK3CA Amplification	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/6275	only gene		CM
input02	PIK3CA MUT* (--)	PIK3CA Amplification	Taselisib	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/1464	only gene		HNSC
input02	PIK3CA MUT* (--)	PIK3CA Amplification	Sulindac,Aspirin,Ibuprofen	Head an neck squamous	Responsive	B	NO	https://civicdb.org/links/evidence_items/7186	only gene		HNSC
input02	PIK3CA MUT* (--)	PIK3CA Amplification	Pictilisib	Ovary	Responsive	C	NO	https://civicdb.org/links/evidence_items/756	only gene		OV
input02	POLD1 MUT* (--), POLD1 MUT* (--), POLD1 MUT* (--)	POLD1 C284Y	Pembrolizumab	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/4776	only alteration type		LUAD
input02	POLD1 MUT* (--), POLD1 MUT* (--), POLD1 MUT* (--)	POLD1 E374K	Pembrolizumab	Non-small cell lung	Responsive	C	NO	https://civicdb.org/links/evidence_items/4777	only alteration type		NSCLC
input02	PTPRD MUT* (--), PTPRD MUT* (--)	PTPRD Mutation	JSI-124	Head an neck squamous	Responsive	D	NO	https://civicdb.org/links/evidence_items/807	only alteration type		HNSC
input02	RAD51B MUT* (--), RAD51B MUT* (--), RAD51B MUT* (--)	RAD51B Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11212	only alteration type		PRAD
input02	RAD51D MUT* (--), RAD51D MUT* (--)	RAD51D Mutation	Olaparib	Prostate adenocarcinoma	Responsive	A	NO	https://civicdb.org/links/evidence_items/11214	only alteration type		PRAD
input02	RB1 MUT* (P23-)	RB1 Mutation	Chemotherapy	Small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1866	only alteration type		SCLC
input02	ROS1 MUT* (F383)	ROS1 Rearrangement	Ceritinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1248	only gene		LUAD
input02	ROS1 MUT* (F383)	ROS1 Rearrangement	Crizotinib	Lung adenocarcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1690	only gene		LUAD
input02	ROS1 MUT* (F383)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/688	only gene		NSCLC
input02	ROS1 MUT* (F383)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	B	NO	https://civicdb.org/links/evidence_items/1030	only gene		NSCLC
input02	ROS1 MUT* (F383)	ROS1 Rearrangement	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7933	only gene		NSCLC
input02	ROS1 MUT* (F383)	ROS1 FUSIONS	Entrectinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/11123	only gene		NSCLC
input02	ROS1 MUT* (F383)	ROS1 Fusion	Crizotinib	Non-small cell lung	Responsive	A	NO	https://civicdb.org/links/evidence_items/7282	only gene		NSCLC
input02	ROS1 MUT* (F383)	ROS1 G2032R	Crizotinib	Lung adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2934	only alteration type		LUAD
input02	ROS1 MUT* (F383)	ROS1 GOPC::ROS1	Lorlatinib	Glioblastoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/7483	only gene		GB
input02	RUNX1 MUT* (--)	RUNX1 Mutation	Cytarabine	Acute myeloid leukemia	Resistant	B	NO	https://civicdb.org/links/evidence_items/411	only alteration type		AML
input02	SOX10 MUT* (--)	SOX10 Loss	Vemurafenib	Cutaneous melanoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/1710	only gene		CM
input02	STK11 MUT* (--)	STK11 Mutation	Pembrolizumab,Nivolumab,Atezolizumab	Lung adenocarcinoma	Resistant	B	NO	https://civicdb.org/links/evidence_items/6441	only alteration type		LUAD
input02	STK11 MUT* (--)	STK11 Loss	Selumetinib,Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1144	only gene		NSCLC
input02	STK11 MUT* (--)	STK11 Loss	Everolimus,Sirolimus	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1620	only gene		NSCLC
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 M237I	MDM2 Inhibitor AMGMDS3	Glioblastoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/4885	only alteration type		GB
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Mutation	Tamoxifen	Breast adenocarcinoma	Resistant	C	NO	https://civicdb.org/links/evidence_items/2784	complete		BRCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Mutation	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/851	complete		BRCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Mutation	Selumetinib,Docetaxel	Non-small cell lung	Responsive	D	NO	https://civicdb.org/links/evidence_items/1145	complete		NSCLC
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Mutation	Pazopanib,Vorinostat	Solid tumors	Responsive	B	YES	https://civicdb.org/links/evidence_items/7540	complete		SOLID
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Mutation	Chemotherapy	Stomach	Responsive	B	NO	https://civicdb.org/links/evidence_items/850	complete		ST
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 R175H	Doxorubicin	Breast adenocarcinoma	Responsive	D	NO	https://civicdb.org/links/evidence_items/319	only alteration type		BRCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 R249	Doxorubicin	Breast adenocarcinoma	Responsive	B	NO	https://civicdb.org/links/evidence_items/399	only alteration type		BRCA
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 R273H	Methotrexate,Doxorubicin	Osteosarcoma	Resistant	D	NO	https://civicdb.org/links/evidence_items/7430	only alteration type		OS
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 R273L	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2286	only alteration type		OV
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Y234C	Cisplatin,Carboplatin	Ovary	Resistant	C	NO	https://civicdb.org/links/evidence_items/2745	only alteration type		OV
input02	TP53 (IRGR332-335X), TP53 (P278L), TP53 (C124Y)	TP53 Loss	Docetaxel	Non-small cell lung	Resistant	D	NO	https://civicdb.org/links/evidence_items/1146	only gene		NSCLC
input02	TSC2 MUT* (--)	TSC2 Q1178*	Everolimus	Thyroid carcinoma	Responsive	C	NO	https://civicdb.org/links/evidence_items/1108	only alteration type		THCA
